# ElÃas Campo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2323032/publications.pdf

Version: 2024-02-01

| 804 | 97,309 | 398 133 | 334 286 |
|---|---|---|---|
| papers | citations | h-index | g-index |

| 884 | 884 | 884 | 67842 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Leukemia, 2022, 36, 583-587. | 3.3 | 5 |
| 2 | Clinicoâ€biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. British Journal of Haematology, 2022, 196, 146-155. | 1.2 | 17 |
| 3 | Revised International Prognostic Index and genetic alterations are associated with early failure to Râ€CHOP in patients with diffuse large Bâ€cell lymphoma. British Journal of Haematology, 2022, 196, 589-598. | 1.2 | 4 |
| 4 | Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements. Blood Advances, 2022, 6, 2361-2372. | 2.5 | 26 |
| 5 | Genetic and phenotypic attributes of splenic marginal zone lymphoma. Blood, 2022, 139, 732-747. | 0.6 | 49 |
| 6 | First external validation of the FLIPIâ€ score in a singleâ€center series of patients with follicular lymphoma. Hematological Oncology, 2022, 40, 297-301. | 0.8 | 0 |
| 7 | The Prognostic Nutritional Index (PNI) is an independent predictor of overall survival in older patients with follicular lymphoma. Leukemia and Lymphoma, 2022, 63, 903-910. | 0.6 | 4 |
| 8 | Towards precision medicine in lymphoid malignancies. Journal of Internal Medicine, 2022, 292, 221-242. | 2.7 | 9 |
| 9 | Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial. Journal of Clinical Oncology, 2022, 40, 1196-1205. | 0.8 | 27 |
| 10 | Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richterâ€™s Transformation. Frontiers in Oncology, 2022, 12, 828471. | 1.3 | 19 |
| 11 | Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma. Journal of Clinical Investigation, 2022, 132, . | 3.9 | 30 |
| 12 | Signatures of TOP1 transcription-associated mutagenesis in cancer and germline. Nature, 2022, 602, 623-631. | 13.7 | 38 |
| 13 | Tâ€cell prolymphocytic leukemia is associated with deregulation of oncogenic <scp>microRNAs</scp> on transcriptional and epigenetic level. Genes Chromosomes and Cancer, 2022, 61, 432-436. | 1.5 | 1 |
| 14 | PanCancer analysis of somatic mutations in repetitive regions reveals recurrent mutations in snRNA U2. Npj Genomic Medicine, 2022, 7, 19. | 1.7 | 2 |
| 15 | Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral TÂcell lymphoma. Cell Reports, 2022, 39, 110695. | 2.9 | 13 |
| 16 | A unifying hypothesis for PNMZL and PTFL: morphological variants with a common molecular profile. Blood Advances, 2022, 6, 4661-4674. | 2.5 | 19 |
| 17 | Serum soluble CD23 levels are an independent predictor of time to first treatment in chronic lymphocytic leukemia. Hematological Oncology, 2022, 40, 588-595. | 0.8 | 0 |
| 18 | The EHA Research Roadmap: Malignant Lymphoid Diseases. HemaSphere, 2022, 6, e726. | 1.2 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood, 2022, 140, 1229-1253. | 0.6 | 512 |
| 20 | ATM germline variants in a young adult with chronic lymphocytic leukemia: 8â€‰years of genomic evolution. Blood Cancer Journal, 2022, 12, . | 2.8 | 2 |
| 21 | Abstract 2502: Unravelling the heterogenous molecular landscape of pediatric post-transplant lymphoproliferative disorders. Cancer Research, 2022, 82, 2502-2502. | 0.4 | 0 |
| 22 | Cell-Free DNA for Genomic Analysis in Primary Mediastinal Large B-Cell Lymphoma. Diagnostics, 2022, 12, 1575. | 1.3 | 6 |
| 23 | Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study. Haematologica, 2021, 106, 682-691. | 1.7 | 10 |
| 24 | RNA editing contributes to epitranscriptome diversity in chronic lymphocytic leukemia. Leukemia, 2021, 35, 1053-1063. | 3.3 | 17 |
| 25 | Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 2021, 137, 1365-1376. | 0.6 | 72 |
| 26 | A Cyclin D1â€“Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research, 2021, 27, 213-225. | 3.2 | 10 |
| 27 | The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal of Haematology, 2021, 106, 428-432. | 1.1 | 1 |
| 28 | IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. Blood, 2021, 137, 2935-2946. | 0.6 | 49 |
| 29 | Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia. Blood, 2021, 137, 2800-2816. | 0.6 | 51 |
| 30 | Preneoplastic Alterations Define CLL DNA Methylome and Persist through Disease Progression and Therapy. Blood Cancer Discovery, 2021, 2, 54-69. | 2.6 | 16 |
| 31 | Mutational Landscape and Tumor Burden Assessed by Cell-free DNA in Diffuse Large B-Cell Lymphoma in a Population-Based Study. Clinical Cancer Research, 2021, 27, 513-521. | 3.2 | 45 |
| 32 | A low lymphocyte-to-monocyte ratio is an independent predictor of poorer survival and higher risk of histological transformation in follicular lymphoma. Leukemia and Lymphoma, 2021, 62, 104-111. | 0.6 | 9 |
| 33 | FYNâ€“TRAF3IP2 induces NF-ÎºB signaling-driven peripheral T-cell lymphoma. Nature Cancer, 2021, 2, 98-113. | 5.7 | 19 |
| 34 | Dynamics of genome architecture and chromatin function during human B cell differentiation and neoplastic transformation. Nature Communications, 2021, 12, 651. | 5.8 | 67 |
| 35 | Age and comorbidity are determining factors in the overall and relative survival of patients with follicular lymphoma. Annals of Hematology, 2021, 100, 1231-1239. | 0.8 | 3 |
| 36 | mmsig: a fitting approach to accurately identify somatic mutational signatures in hematological malignancies. Communications Biology, 2021, 4, 424. | 2.0 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma. Leukemia, 2021, 35, 2635-2649. | 3.3 | 32 |
| 38 | Taking gray zone lymphomas out of the shadows. Blood, 2021, 137, 1703-1704. | 0.6 | 8 |
| 39 | Consumption of Ultra-Processed Food and Drinks and Chronic Lymphocytic Leukemia in the MCC-Spain Study. International Journal of Environmental Research and Public Health, 2021, 18, 5457. | 1.2 | 10 |
| 40 | MAPK and JAK-STAT pathways dysregulation in plasmablastic lymphoma. Haematologica, 2021, 106, 2682-2693. | 1.7 | 44 |
| 41 | The Protein Landscape of Chronic Lymphocytic Leukemia (CLL). Blood, 2021, , . | 0.6 | 17 |
| 42 | SOX11, CD70, and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma. Blood, 2021, 138, 2202-2215. | 0.6 | 22 |
| 43 | Vulnerabilities in the tumor and microenvironment in follicular lymphoma. Hematological Oncology, 2021, 39, 83-87. | 0.8 | 3 |
| 44 | Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPHOS activity in chronic lymphocytic leukemia. Nature Cancer, 2021, 2, 853-864. | 5.7 | 32 |
| 45 | ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status. Cancers, 2021, 13, 3803. | 1.7 | 3 |
| 46 | SAMHD1 mutations in mantle cell lymphoma are recurrent and confer in vitro resistance to nucleoside analogues. Leukemia Research, 2021, 107, 106608. | 0.4 | 6 |
| 47 | The molecular hallmarks of primary and secondary vitreoretinal lymphoma. Blood Advances, 2021, , . | 2.5 | 16 |
| 48 | Clinicobiological Characteristics and Outcomes of Patients with T-Cell Large Granular Lymphocytic Leukemia and Chronic Lymphoproliferative Disorder of Natural Killer Cells from a Single Institution. Cancers, 2021, 13, 3900. | 1.7 | 12 |
| 49 | Prognostic ability of five clinical risk scores in follicular lymphoma: A singleâ€center evaluation. Hematological Oncology, 2021, 39, 639-649. | 0.8 | 6 |
| 50 | Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact. Haematologica, 2021, 106, 1754-1757. | 1.7 | 2 |
| 51 | Clinical Validation of MCL35 in Mantle Cell Lymphoma Patients â‰¥65 Years Receiving Bendamustine-Rituximab. Blood, 2021, 138, 3517-3517. | 0.6 | 1 |
| 52 | Interleukin-10 receptor signaling promotes the maintenance of a PD-1int TCF-1+ CD8+ TÂcell population that sustains anti-tumor immunity. Immunity, 2021, 54, 2825-2841.e10. | 6.6 | 57 |
| 53 | Targeting IRAK4 disrupts inflammatory pathways and delays tumor development in chronic lymphocytic leukemia. Leukemia, 2020, 34, 100-114. | 3.3 | 31 |
| 54 | Specific NOTCH1 antibody targets DLL4-induced proliferation, migration, and angiogenesis in NOTCH1-mutated CLL cells. Oncogene, 2020, 39, 1185-1197. | 2.6 | 22 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica, 2020, 105, 1032-1041. | 1.7 | 29 |
| 56 | Reconstruction of rearranged Tâ€cell receptor loci by whole genome and transcriptome sequencing gives insights into the initial steps of Tâ€cell prolymphocytic leukemia. Genes Chromosomes and Cancer, 2020, 59, 261-267. | 1.5 | 16 |
| 57 | Expansion of PD1-positive T Cells in Nodal Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2020, 44, 657-664. | 2.1 | 21 |
| 58 | The Number of Signaling Pathways Altered by Driver Mutations in Chronic Lymphocytic Leukemia Impacts Disease Outcome. Clinical Cancer Research, 2020, 26, 1507-1515. | 3.2 | 13 |
| 59 | Adherence to the 2018 WCRF/AICR cancer prevention guidelines and chronic lymphocytic leukemia in the MCC-Spain study. Cancer Epidemiology, 2020, 64, 101629. | 0.8 | 12 |
| 60 | The Dietary Inflammatory Index and Chronic Lymphocytic Leukaemia in the MCC Spain Study. Nutrients, 2020, 12, 48. | 1.7 | 2 |
| 61 | Molecular Pathogenesis of Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 795-807. | 0.9 | 40 |
| 62 | Pathology of primary splenic B-cell lymphomas: a review. Diagnostic Histopathology, 2020, 26, 398-406. | 0.2 | 1 |
| 63 | Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma. Haematologica, 2020, 105, e408-e411. | 1.7 | 13 |
| 64 | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma in Asia Frequently Shows SETD2 Alterations. Cancers, 2020, 12, 3539. | 1.7 | 22 |
| 65 | The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome. Nature Cancer, 2020, 1, 1066-1081. | 5.7 | 51 |
| 66 | Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330. | 5.8 | 60 |
| 67 | PI3KÎ´ inhibition reshapes follicular lymphomaâ€“immune microenvironment cross talk and unleashes the activity of venetoclax. Blood Advances, 2020, 4, 4217-4231. | 2.5 | 23 |
| 68 | Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome Research, 2020, 30, 1217-1227. | 2.4 | 35 |
| 69 | Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia. Scientific Reports, 2020, 10, 22153. | 1.6 | 16 |
| 70 | Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. Blood Advances, 2020, 4, 5652-5665. | 2.5 | 67 |
| 71 | Sampling time-dependent artifacts in single-cell genomics studies. Genome Biology, 2020, 21, 112. | 3.8 | 55 |
| 72 | High serum levels of IL-2R, IL-6, and TNF-Î± are associated with higher tumor burden and poorer outcome of follicular lymphoma patients in the rituximab era. Leukemia Research, 2020, 94, 106371. | 0.4 | 7 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation. Haematologica, 2020, 105, 2864-2867. | 1.7 | 11 |
| 74 | Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial. Frontiers in Immunology, 2020, 11, 482. | 2.2 | 77 |
| 75 | Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer Journal, 2020, 10, 31. | 2.8 | 23 |
| 76 | Chronic lymphocytic leukaemia and prolymphocytic leukaemia. Two coins or two sides of the same coin?. Haematologica, 2020, 105, e484. | 1.7 | 2 |
| 77 | IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. Nature Communications, 2020, 11, 3390. | 5.8 | 24 |
| 78 | Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood, 2020, 136, 1419-1432. | 0.6 | 131 |
| 79 | Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica, 2020, 105, 2205-2217. | 1.7 | 47 |
| 80 | HHV8-positive, EBV-positive Hodgkin lymphoma-like large B cell lymphoma: expanding the spectrum of HHV8 and EBV-associated lymphoproliferative disorders. International Journal of Hematology, 2020, 112, 734-740. | 0.7 | 7 |
| 81 | Reproducibility of histologic prognostic parameters for mantle cell lymphoma: cytology, Ki67, p53 and SOX11. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 259-267. | 1.4 | 15 |
| 82 | Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. Annual Review of Pathology: Mechanisms of Disease, 2020, 15, 149-177. | 9.6 | 17 |
| 83 | Minimal spatial heterogeneity in chronic lymphocytic leukemia at diagnosis. Leukemia, 2020, 34, 1929-1933. | 3.3 | 2 |
| 84 | Timing the initiation of multiple myeloma. Nature Communications, 2020, 11, 1917. | 5.8 | 99 |
| 85 | Distinct molecular profile of IRF4-rearranged large B-cell lymphoma. Blood, 2020, 135, 274-286. | 0.6 | 81 |
| 86 | The IGLV3-21R110 Defines a Subset of Chronic Lymphocytic Leukemia with Intermediate Epigenetic Subtype and Poor Outcome. Blood, 2020, 136, 43-44. | 0.6 | 1 |
| 87 | Mutational Profile and Copy Number Alterations of Follicular Lymphoma Patients with Different Clinical Behavior. Blood, 2020, 136, 7-8. | 0.6 | 0 |
| 88 | The CLL-1100 Project: Towards Complete Genomic Characterization and Improved Prognostics for CLL. Blood, 2020, 136, 3-4. | 0.6 | 2 |
| 89 | Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma. Haematologica, 2019, 104, 778-788. | 1.7 | 17 |
| 90 | Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nature Communications, 2019, 10, 3615. | 5.8 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | A practical guide for mutational signature analysis in hematological malignancies. Nature Communications, 2019, 10, 2969. | 5.8 | 145 |
| 92 | Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. Journal of Experimental and Clinical Cancer Research, 2019, 38, 446. | 3.5 | 28 |
| 93 | The U1 spliceosomal RNA is recurrently mutated in multiple cancers. Nature, 2019, 574, 712-716. | 13.7 | 128 |
| 94 | Reproducing the molecular subclassification of peripheral T-cell lymphomaâ€“NOS by immunohistochemistry. Blood, 2019, 134, 2159-2170. | 0.6 | 120 |
| 95 | Different time-dependent changes of risk for evolution in chronic lymphocytic leukemia with mutated or unmutated antigen B cell receptors. Leukemia, 2019, 33, 1801-1805. | 3.3 | 5 |
| 96 | GENOME WIDE-ANALYSIS OF T(14;18)-NEGATIVE FOLLICULAR LYMPHOMA. Hematological Oncology, 2019, 37, 144-145. | 0.8 | 0 |
| 97 | MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS. Hematological Oncology, 2019, 37, 186-187. | 0.8 | 0 |
| 98 | Increased tumour angiogenesis in SOX11â€positive mantle cell lymphoma. Histopathology, 2019, 75, 704-714. | 1.6 | 16 |
| 99 | High TNFRSF14 and low BTLA are associated with poor prognosis in Follicular Lymphoma and in Diffuse Large B-cell Lymphoma transformation. Journal of Clinical and Experimental Hematopathology: JCEH, 2019, 59, 1-16. | 0.3 | 36 |
| 100 | Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell deathâ€ligand 1 (PDâ€L1) axis in postâ€transplant lymphoproliferative disorders: association with Epsteinâ€“Barr virus, PDâ€L1 copy number alterations, and outcome. Histopathology, 2019, 75, 799-812. | 1.6 | 29 |
| 101 | Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma. Haematologica, 2019, 104, 1822-1829. | 1.7 | 71 |
| 102 | Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. Blood, 2019, 133, 1664-1676. | 0.6 | 184 |
| 103 | Kikuchi-Fujimoto disease and breast implants: is there a relationship?. Haematologica, 2019, 104, e581-e584. | 1.7 | 2 |
| 104 | PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE. Hematological Oncology, 2019, 37, 395-397. | 0.8 | 0 |
| 105 | GENOTYPING PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS. Hematological Oncology, 2019, 37, 346-347. | 0.8 | 0 |
| 106 | CCND2 and CCND3 hijack immunoglobulin light-chain enhancers in cyclin D1â^' mantle cell lymphoma. Blood, 2019, 133, 940-951. | 0.6 | 77 |
| 107 | Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia. International Journal of Cancer, 2019, 144, 2762-2773. | 2.3 | 8 |
| 108 | Differential expression of long nonâ€coding <scp>RNA</scp>s are related to proliferation and histological diversity in follicular lymphomas. British Journal of Haematology, 2019, 184, 373-383. | 1.2 | 12 |

| # | Article | IF | Citations |
|---|---|---|---|
| 109 | Insulinâ€like growth factor levels and chronic lymphocytic leukaemia: results from the MCC â€Spain and EpiLymphâ€Spain studies. British Journal of Haematology, 2019, 185, 608-612. | 1.2 | 1 |
| 110 | Development of a Novel Anti-CD19 Chimeric Antigen Receptor: A Paradigm for an Affordable CAR T Cell Production at Academic Institutions. Molecular Therapy - Methods and Clinical Development, 2019, 12, 134-144. | 1.8 | 77 |
| 111 | Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. British Journal of Haematology, 2019, 184, 753-759. | 1.2 | 49 |
| 112 | Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. Haematologica, 2019, 104, 576-586. | 1.7 | 40 |
| 113 | Control of chronic lymphocytic leukemia development by clonally-expanded CD8+ T-cells that undergo functional exhaustion in secondary lymphoid tissues. Leukemia, 2019, 33, 625-637. | 3.3 | 55 |
| 114 | Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. Haematologica, 2019, 104, 360-369. | 1.7 | 42 |
| 115 | Expression of the transcribed ultraconserved region 70 and the related long nonâ€coding <scp>RNA AC</scp>092652.2â€202 has prognostic value in Chronic Lymphocytic Leukaemia. British Journal of Haematology, 2019, 184, 1045-1050. | 1.2 | 10 |
| 116 | A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncology, The, 2018, 19, 549-561. | 5.1 | 165 |
| 117 | Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood, 2018, 131, 2283-2296. | 0.6 | 106 |
| 118 | Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. New England Journal of Medicine, 2018, 378, 1396-1407. | 13.9 | 1,443 |
| 119 | The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma. Oncogene, 2018, 37, 1830-1844. | 2.6 | 69 |
| 120 | Established and suggested exposures on CLL/SLL etiology: Results from the CLL-MCC-Spain study. Cancer Epidemiology, 2018, 52, 106-111. | 0.8 | 7 |
| 121 | A retinoic acid-dependent stroma-leukemia crosstalk promotes chronic lymphocytic leukemia progression. Nature Communications, 2018, 9, 1787. | 5.8 | 22 |
| 122 | Expression of a truncated B lymphocyte-induced maturation protein-1 isoform is associated with an incomplete plasmacytic differentiation program in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 482-485. | 0.6 | 0 |
| 123 | Whole-genome sequencing of chronic lymphocytic leukaemia reveals distinct differences in the mutational landscape between IgHVmut and IgHVunmut subgroups. Leukemia, 2018, 32, 332-342. | 3.3 | 49 |
| 124 | Clinicopathological and genomic analysis of double-hit follicular lymphoma: comparison with high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements. Modern Pathology, 2018, 31, 313-326. | 2.9 | 42 |
| 125 | Is there a role for minimal residual disease monitoring in the management of patients with hairyâ€cell leukaemia?. British Journal of Haematology, 2018, 183, 127-129. | 1.2 | 10 |
| 126 | Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia, 2018, 32, 645-653. | 3.3 | 91 |

| # | Article | IF | Citations |
|---|---|---|---|
| 127 | Prospective subgroup analyses of the randomized <scp>MCL</scp>â€002 (<scp>SPRINT</scp>) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. British Journal of Haematology, 2018, 180, 224-235. | 1.2 | 10 |
| 128 | The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia. Leukemia and Lymphoma, 2018, 59, 2318-2326. | 0.6 | 5 |
| 129 | Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. Leukemia, 2018, 32, 675-684. | 3.3 | 141 |
| 130 | TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics. Haematologica, 2018, 103, 1956-1968. | 1.7 | 94 |
| 131 | Molecular classification of primary mediastinal large B-cell lymphoma using routinely available tissue specimens. Blood, 2018, 132, 2401-2405. | 0.6 | 64 |
| 132 | Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue. Annals of Oncology, 2018, 29, 2363-2370. | 0.6 | 89 |
| 133 | Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia. Blood, 2018, 132, 2375-2388. | 0.6 | 48 |
| 134 | Mantle Cell Lymphoma Biology. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S97-S98. | 0.2 | 1 |
| 135 | A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood, 2018, 132, 413-422. | 0.6 | 89 |
| 136 | The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. Nature Medicine, 2018, 24, 868-880. | 15.2 | 157 |
| 137 | Adherence to the Western, Prudent, and Mediterranean dietary patterns and chronic lymphocytic leukemia in the MCC-Spain study. Haematologica, 2018, 103, 1881-1888. | 1.7 | 21 |
| 138 | SOX11, a key oncogenic factor in mantle cell lymphoma. Current Opinion in Hematology, 2018, 25, 299-306. | 1.2 | 42 |
| 139 | Intravascular large B-cell lymphoma: a chameleon with multiple faces and many masks. Blood, 2018, 132, 1561-1567. | 0.6 | 161 |
| 140 | A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature, 2018, 560, 387-391. | 13.7 | 276 |
| 141 | Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. Journal of Clinical Investigation, 2018, 128, 4132-4147. | 3.9 | 31 |
| 142 | Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. Blood, 2018, 132, 922-922. | 0.6 | 2 |
| 143 | Abstract LB-083: Targeting IRAK4 disrupts inflammatory pathways and tumor microenvironment in chronic lymphocytic leukemia regardless MYD88 mutational status. , 2018, , . | | 0 |
| 144 | Targeting IRAK4 Disrupts Inflammatory Pathways and Delays Tumor Development in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 2650-2650. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 145 | An Epigenetic Mitotic Score Tracks the Proliferative History and Capacity of CLL Samples at Diagnosis and Is Associated with Clinical Outcome. Blood, 2018, 132, 1842-1842. | 0.6 | 2 |
| 146 | Recurrent Mutations in EGR2 Direct Specific Epigenetic Reconfiguration in Chronic Lymphocytic Leukemia. Blood, 2018, 132, 650-650. | 0.6 | 0 |
| 147 | Large B-Cell Lymphomas in Pediatric and Young Adults Display Clinically Relevant Molecular Features Distinguishable from Adult Counterparts. Blood, 2018, 132, 1567-1567. | 0.6 | 0 |
| 148 | Lesiones cerebrales en trasplante renal de larga evoluciÃ³n, Â¿linfoma cerebral primario vs. toxoplasmosis cerebral?. NeurologÃa, 2017, 32, 268-270. | 0.3 | 2 |
| 149 | Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma. Leukemia, 2017, 31, 83-91. | 3.3 | 87 |
| 150 | Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12Âyears follow-up of a phase 2 trial. Annals of Hematology, 2017, 96, 639-646. | 0.8 | 7 |
| 151 | Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 764-769. | 3.3 | 100 |
| 152 | Distinctive Histogenesis and Immunological Microenvironment Based on Transcriptional Profiles of Follicular Dendritic Cell Sarcomas. Molecular Cancer Research, 2017, 15, 541-552. | 1.5 | 24 |
| 153 | HHV8-related lymphoid proliferations: a broad spectrum of lesions from reactive lymphoid hyperplasia to overt lymphoma. Modern Pathology, 2017, 30, 745-760. | 2.9 | 60 |
| 154 | Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature Communications, 2017, 8, 14175. | 5.8 | 75 |
| 155 | Numerous Ontogenetic Roads to Mantle Cell Lymphoma. American Journal of Pathology, 2017, 187, 1454-1458. | 1.9 | 11 |
| 156 | Improved classification of leukemic B-cell lymphoproliferative disorders using a transcriptional and genetic classifier. Haematologica, 2017, 102, e360-e363. | 1.7 | 27 |
| 157 | Mutations of MAP2K1 are frequent in pediatric-type follicular lymphoma and result in ERK pathway activation. Blood, 2017, 130, 323-327. | 0.6 | 69 |
| 158 | SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood, 2017, 130, 501-513. | 0.6 | 90 |
| 159 | Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical Cancer Research, 2017, 23, 5292-5301. | 3.2 | 27 |
| 160 | High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leukemia Research, 2017, 59, 20-25. | 0.4 | 35 |
| 161 | LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas. American Journal of Surgical Pathology, 2017, 41, 877-886. | 2.1 | 19 |
| 162 | Pathology and classification of aggressive mature <scp>B</scp>â€cell lymphomas. Hematological Oncology, 2017, 35, 80-83. | 0.8 | 3 |

| # | Article | IF | Citations |
|---|---|---|---|
| 163 | Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma. Journal of Hematology and Oncology, 2017, 10, 80. | 6.9 | 11 |
| 164 | Refining the prognostic impact of the cell of origin in diffuse large B-cell lymphoma. Annals of Oncology, 2017, 28, 918-920. | 0.6 | 1 |
| 165 | Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma. British Journal of Haematology, 2017, 177, 557-561. | 1.2 | 14 |
| 166 | Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Annals of Hematology, 2017, 96, 405-410. | 0.8 | 12 |
| 167 | The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-Î¹B mutational status. Haematologica, 2017, 102, e447-e451. | 1.7 | 18 |
| 168 | Lenalidomide in combination with R-ESHAP in patients with relapsed or refractory diffuse large B-cell lymphoma: A phase 2 study from the Spanish group GELTAMO. Hematological Oncology, 2017, 35, 345-345. | 0.8 | 0 |
| 169 | Clinical and Biological Significance of Y Chromosome Loss in a Series of 2,423 Male Patients with MDS and CMML. Leukemia Research, 2017, 55, S122-S123. | 0.4 | 0 |
| 170 | Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma. Annals of Oncology, 2017, 28, 2799-2805. | 0.6 | 22 |
| 171 | GENE-EXPRESSION PROFILING PREDICTS DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. Hematological Oncology, 2017, 35, 113-115. | 0.8 | 2 |
| 172 | ANTI-TUMOR ACTIVITY OF DARATUMUMAB, A NOVEL HUMAN ANTI CD38 MONOCLONAL ANTIBODY, IN IN VITRO AND IN VIVO MODELS OF B-CELL NON-HODGKIN LYMPHOMA. Hematological Oncology, 2017, 35, 46-47. | 0.8 | 1 |
| 173 | INTEGRATIVE MUTATIONAL ANALYSIS OF PEDIATRICâ€TYPE FOLLICULAR LYMPHOMA REVEALS TNFRSF14 AND MAP2K1 AS THE MOST FREQUENTLY MUTATED GENES. Hematological Oncology, 2017, 35, 149-150. | 0.8 | 0 |
| 174 | Progression-free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era. Hematological Oncology, 2017, 35, 360-361. | 0.8 | 4 |
| 175 | Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets. Blood, 2017, 130, 1819-1831. | 0.6 | 62 |
| 176 | Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89. | 0.4 | 9 |
| 177 | Clinicopathological characteristics and genomic profile of primary sinonasal tract diffuse large B cell lymphoma (<scp>DLBCL</scp>) reveals gain at 1q31 and <scp>RGS</scp>1 encoding protein; high <scp>RGS</scp>1 immunohistochemical expression associates with poor overall survival in <scp>DLBCL</scp> not otherwise specified (<scp>NOS</scp>). Histopathology, 2017, 70, 595-621. | 1.6 | 41 |
| 178 | T-cell subsets in lymph nodes identify a subgroup of follicular lymphoma patients with favorable outcome. Leukemia and Lymphoma, 2017, 58, 842-850. | 0.6 | 6 |
| 179 | Impact of the functional CD5 polymorphism A471V on the response of chronic lymphocytic leukaemia to conventional chemotherapy regimens. British Journal of Haematology, 2017, 177, 147-150. | 1.2 | 8 |
| 180 | The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemiaâ€“Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 1493-1505. | 3.2 | 38 |

| # | Article | IF | Citations |
|---|---|---|---|
| 181 | Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2017, 28, iv62-iv71. | 0.6 | 387 |
| 182 | New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies. Journal of Clinical Oncology, 2017, 35, 1668-1677. | 0.8 | 102 |
| 183 | Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. Journal of Clinical Oncology, 2017, 35, 1905-1912. | 0.8 | 143 |
| 184 | Chronic Lymphocytic Leukemia; Pathology and Genetics. , 2017, , . | | 0 |
| 185 | Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing. Oncotarget, 2017, 8, 16463-16472. | 0.8 | 43 |
| 186 | Abstract 2169: Pharmacological modulation of CXCL12-CXCR4 intracellular trafficking potentiates thein vitroandin vivoactivity of the BET bromodomain inhibitor CPI203 in diffuse large B-cell lymphoma. , 2017, , . | | 0 |
| 187 | Abstract 2161: Pharmacological downregulation of BFL-1 by the BET bromodomain inhibitor CPI203 overcomes ABT-199 resistance in MYC+/BCL2+ double hit lymphoma. Cancer Research, 2017, 77, 2161-2161. | 0.4 | 2 |
| 188 | SAT0353â€...Relationship between Disruption of The Muscular Layer in Temporal Artery Biopsies of GCA Patients and The Development of Aortic Dilatation/aneurysm during Follow-Up. Annals of the Rheumatic Diseases, 2016, 75, 794.3-795. | 0.5 | 0 |
| 189 | Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. Medicine (United States), 2016, 95, e2368. | 0.4 | 55 |
| 190 | <scp>LPL</scp> gene expression is associated with poor prognosis in <scp>CLL</scp> and closely related to <scp>NOTCH</scp>1 mutations. European Journal of Haematology, 2016, 97, 175-182. | 1.1 | 13 |
| 191 | Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v91-v102. | 0.6 | 102 |
| 192 | Genes encoding members of the <scp>JAK</scp>â€<scp>STAT</scp> pathway or epigenetic regulators are recurrently mutated in Tâ€cell prolymphocytic leukaemia. British Journal of Haematology, 2016, 173, 265-273. | 1.2 | 64 |
| 193 | Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2016, 534, S11-S12. | 13.7 | 519 |
| 194 | Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma. Blood, 2016, 128, 2666-2670. | 0.6 | 82 |
| 195 | Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica, 2016, 101, 959-967. | 1.7 | 57 |
| 196 | Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma. Cancer Cell, 2016, 29, 494-507. | 7.7 | 93 |
| 197 | Definition of MYC genetic heteroclonality in diffuse large B-cell lymphoma with 8q24 rearrangement and its impact on protein expression. Modern Pathology, 2016, 29, 844-853. | 2.9 | 7 |
| 198 | Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes. Acta Haematologica, 2016, 135, 94-100. | 0.7 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 199 | The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood, 2016, 127, 2375-2390. | 0.6 | 5,965 |
| 200 | Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. Blood, 2016, 128, 1101-1111. | 0.6 | 115 |
| 201 | Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. Haematologica, 2016, 101, 1002-1009. | 1.7 | 43 |
| 202 | Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood, 2016, 127, 2122-2130. | 0.6 | 260 |
| 203 | miRNA expression profiling divides follicular dendritic cell sarcomas into two groups, related to fibroblasts and myopericytomas or Castleman's disease. European Journal of Cancer, 2016, 64, 159-166. | 1.3 | 16 |
| 204 | Genetic evolution in chronic lymphocytic leukaemia. Best Practice and Research in Clinical Haematology, 2016, 29, 67-78. | 0.7 | 1 |
| 205 | Genetic Predisposition to Chronic Lymphocytic Leukemia Is Mediated by a BMF Super-Enhancer Polymorphism. Cell Reports, 2016, 16, 2061-2067. | 2.9 | 58 |
| 206 | Clinical impact of MYD88 mutations in chronic lymphocytic leukemia. Blood, 2016, 127, 1611-1613. | 0.6 | 8 |
| 207 | Decoding the DNA Methylome of Mantle Cell Lymphoma in the Light of the Entire B Cell Lineage. Cancer Cell, 2016, 30, 806-821. | 7.7 | 103 |
| 208 | The International Human Epigenome Consortium: A Blueprint for Scientific Collaboration and Discovery. Cell, 2016, 167, 1145-1149. | 13.5 | 404 |
| 209 | FRI0361â€...The Extension of Inflammatory Infiltrates or Intimal Hyperplasia in Temporal Arteries Do Not Significantly Predict CTA-Detection of Aortic Thickening in Newly-Diagnosed Patients with biopsy-proven Giant-Cell Arteritis. Annals of the Rheumatic Diseases, 2016, 75, 565.2-566. | 0.5 | 0 |
| 210 | Shelterins, a genetic crossroad in CLL. Blood, 2016, 128, 2279-2280. | 0.6 | 3 |
| 211 | NOTCH1, TP53, and MAP2K1 Mutations in Splenic Diffuse Red Pulp Small B-cell Lymphoma Are Associated With Progressive Disease. American Journal of Surgical Pathology, 2016, 40, 192-201. | 2.1 | 40 |
| 212 | Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327. | 1.5 | 7 |
| 213 | MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Clinical Cancer Research, 2016, 22, 2755-2764. | 3.2 | 55 |
| 214 | The European Hematology Association Roadmap for European Hematology Research: a consensus document. Haematologica, 2016, 101, 115-208. | 1.7 | 67 |
| 215 | In this issue: small B cell lymphomas, more than just a size. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 125-126. | 1.4 | 0 |
| 216 | Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2016, 22, 6217-6227. | 3.2 | 26 |

| # | Article | IF | Citations |
|---|---|---|---|
| 217 | SOX11 defines two different subtypes of mantle cell lymphoma through transcriptional regulation of BCL6. Leukemia, 2016, 30, 1596-1599. | 3.3 | 45 |
| 218 | Indolent lymphomas in the pediatric population: follicular lymphoma, IRF4/MUM1+ lymphoma, nodal marginal zone lymphoma and chronic lymphocytic leukemia. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 141-157. | 1.4 | 73 |
| 219 | The heterogeneity of follicular lymphomas: from early development to transformation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 127-139. | 1.4 | 31 |
| 220 | The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 259-275. | 1.4 | 97 |
| 221 | Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status. Leukemia and Lymphoma, 2016, 57, 717-720. | 0.6 | 13 |
| 222 | Mantle cell lymphomaâ€"a spectrum from indolent to aggressive disease. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 245-257. | 1.4 | 65 |
| 223 | Notch1 Signaling in NOTCH1-Mutated Mantle Cell Lymphoma Depends on DLL4 and Is a Potential Target for Specific Antibody Therapy. Blood, 2016, 128, 1846-1846. | 0.6 | 2 |
| 224 | Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. Blood, 2016, 128, 4096-4096. | 0.6 | 1 |
| 225 | Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. Blood, 2016, 128, 4376-4376. | 0.6 | 1 |
| 226 | Prognostic significance of the proliferation signature in mantle cell lymphoma measured using digital gene expression in formalin-fixed paraffin-embedded tissue biopsies.. Journal of Clinical Oncology, 2016, 34, 7510-7510. | 0.8 | 2 |
| 227 | CD69 expression potentially predicts response to bendamustine and its modulation by ibrutinib or idelalisib enhances cytotoxic effect in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 5507-5520. | 0.8 | 23 |
| 228 | Benign and Malignant Lymphoid Lesions of the Head and Neck. , 2016, , 579-611. | | 0 |
| 229 | Clinical Impact of the Quantitative Subclonal Architecture in Chronic Lymphocytic Leukemia. Blood, 2016, 128, 2024-2024. | 0.6 | 0 |
| 230 | Aberrant Expression of the SOX11 Oncogene in Mantle Cell Lymphoma Is Associated with Activation and De Novo 3D Looping of a Distant Enhancer Element. Blood, 2016, 128, 459-459. | 0.6 | 0 |
| 231 | Clinical Impact of the Presence of a Diffuse Large B-Cell Lymphoma (DLBCL) Component in the Outcome of Untreated Patients with Follicular Lymphoma (FL). Blood, 2016, 128, 3043-3043. | 0.6 | 2 |
| 232 | Tailored Approaches for Refined Prognostication in Chronic Lymphocytic Leukemia Patients with Mutated Versus Unmutated Immunoglobulin Receptors. Blood, 2016, 128, 3199-3199. | 0.6 | 0 |
| 233 | Comprehensive Genomic Analysis of Adult Burkitt Lymphoma Identifies the B-Cell Receptor Signaling Pathway As a Potential Therapeutic Target. Blood, 2016, 128, 4095-4095. | 0.6 | 0 |
| 234 | VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas. Blood, 2016, 128, 2741-2741. | 0.6 | 1 |

| # | Article | IF | Citations |
|---|---|---|---|
| 235 | Integrating Genomic Alterations in Diffuse Large B-Cell Lymphoma Identifies New Relevant Pathways and Potential Therapeutic Targets. Blood, 2016, 128, 152-152. | 0.6 | 0 |
| 236 | Whole-Genome Analysis of the Chromatin Structure in Multiple Myeloma. Blood, 2016, 128, 118-118. | 0.6 | 0 |
| 237 | Detection of chromothripsisâ€like patterns with a custom array platform for chronic lymphocytic leukemia. Genes Chromosomes and Cancer, 2015, 54, 668-680. | 1.5 | 23 |
| 238 | MYC in DLBCL: partners matter. Blood, 2015, 126, 2439-2440. | 0.6 | 29 |
| 239 | Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma. Blood, 2015, 125, 1137-1145. | 0.6 | 110 |
| 240 | Mantle cell lymphoma: evolving management strategies. Blood, 2015, 125, 48-55. | 0.6 | 155 |
| 241 | Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. Blood, 2015, 126, 195-202. | 0.6 | 50 |
| 242 | Aberrant Epstein-Barr virus antibody patterns and chronic lymphocytic leukemia in a Spanish multicentric case-control study. Infectious Agents and Cancer, 2015, 10, 5. | 1.2 | 2 |
| 243 | Paraspinal extramedullary hematopoiesis in hereditary spherocytosis with a concurrent follicular lymphoma: case report and review of the literature. Diagnostic Pathology, 2015, 10, 158. | 0.9 | 2 |
| 244 | Identification of Primary Mediastinal Large B-cell Lymphoma at Nonmediastinal Sites by Gene Expression Profiling. American Journal of Surgical Pathology, 2015, 39, 1322-1330. | 2.1 | 63 |
| 245 | Diffuse Large B-cell Lymphomas of Immunoblastic Type Are a Major Reservoir for MYC-IGH Translocations. American Journal of Surgical Pathology, 2015, 39, 61-66. | 2.1 | 34 |
| 246 | Whole-genome fingerprint of the DNA methylome during human B cell differentiation. Nature Genetics, 2015, 47, 746-756. | 9.4 | 278 |
| 247 | Molecular pathogenesis of CLL and its evolution. International Journal of Hematology, 2015, 101, 219-228. | 0.7 | 19 |
| 248 | Virtual microscopy in the undergraduate teaching of pathology. Journal of Pathology Informatics, 2015, 6, 1. | 0.8 | 35 |
| 249 | WHO classification for B-cell lymphoma: update in 2015. Annals of Oncology, 2015, 26, vii17. | 0.6 | 0 |
| 250 | A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. Nature Communications, 2015, 6, 10001. | 5.8 | 266 |
| 251 | Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. Pharmacogenomics Journal, 2015, 15, 363-371. | 0.9 | 18 |
| 252 | Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome Research, 2015, 25, 478-487. | 2.4 | 118 |

| # | Article | IF | Citations |
|---|---|---|---|
| 253 | Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design. Gaceta Sanitaria, 2015, 29, 308-315. | 0.6 | 158 |
| 254 | Molecular Evidence for Antigen Drive in the Natural History of Mantle Cell Lymphoma. American Journal of Pathology, 2015, 185, 1740-1748. | 1.9 | 13 |
| 255 | Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature, 2015, 526, 519-524. | 13.7 | 749 |
| 256 | Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Annals of Hematology, 2015, 94, 803-812. | 0.8 | 74 |
| 257 | Seroreactivity against Merkel cell polyomavirus and other polyomaviruses in chronic lymphocytic leukaemia, the MCC-Spain study. Journal of General Virology, 2015, 96, 2286-2292. | 1.3 | 9 |
| 258 | MYC Alterations in Diffuse Large B-Cell Lymphomas. Seminars in Hematology, 2015, 52, 97-106. | 1.8 | 80 |
| 259 | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue of the Salivary Glands: A Multicenter, International Experience of 248 Patients (IELSG 41). Oncologist, 2015, 20, 1149-1153. | 1.9 | 52 |
| 260 | <scp>CD8</scp>â€positive peripheral Tâ€cell lymphoma with aberrant expression of <scp>CD20</scp> and concurrent in situ follicular lymphoma. Journal of Cutaneous Pathology, 2015, 42, 66-72. | 0.7 | 6 |
| 261 | Survival of human lymphoma cells requires B-cell receptor engagement by self-antigens. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 13447-13454. | 3.3 | 143 |
| 262 | Genomic and immunohistochemical profiles of enteropathy-associated T-cell lymphoma in Japan. Modern Pathology, 2015, 28, 1286-1296. | 2.9 | 58 |
| 263 | Plasma cell and terminal B-cell differentiation in mantle cell lymphoma mainly occur in the SOX11-negative subtype. Modern Pathology, 2015, 28, 1435-1447. | 2.9 | 35 |
| 264 | Mutations in the Toll-like receptor/MYD88 pathway in young (â‰50 years) CLL patients. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, S203. | 0.2 | 0 |
| 265 | Hairy cell leukaemia-variant: Disease features and treatment. Best Practice and Research in Clinical Haematology, 2015, 28, 253-263. | 0.7 | 47 |
| 266 | The Î³-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells. Leukemia, 2015, 29, 96-106. | 3.3 | 62 |
| 267 | A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. Leukemia, 2015, 29, 598-605. | 3.3 | 129 |
| 268 | Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia, 2015, 29, 329-336. | 3.3 | 253 |
| 269 | Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, and ATM Mutations in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 4138-4138. | 0.6 | 1 |
| 270 | The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget, 2015, 6, 22734-22749. | 0.8 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 271 | Bcl-2highmantle cell lymphoma cells are sensitized to acadesine with ABT-199. Oncotarget, 2015, 6, 21159-21172. | 0.8 | 16 |
| 272 | Abstract 5317: Preclinical evaluation of IQS019, a novel BCR kinase inhibitor, in in vitro and in vivo models of non-Hodgkin lymphoma. , 2015, , . | | 0 |
| 273 | Abstract 2584: Specific antitumor activity of the splicing modulator sudemycin and cooperation with ibrutinib in chronic lymphocytic leukemia. , 2015, , . | | 0 |
| 274 | Gene Expression Profiling Signatures Allow the Identification of Unclassifiable Leukemic B-Cell Lymphoid Neoplasms. Blood, 2015, 126, 3902-3902. | 0.6 | 0 |
| 275 | CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263. | 0.6 | 0 |
| 276 | Small-vessel vasculitis with prominent IgG4 positive plasma cell infiltrates as potential part of the spectrum of IgG4-related disease: a case report. Clinical and Experimental Rheumatology, 2015, 33, S-138-41. | 0.4 | 4 |
| 277 | In vivo intratumoral Epsteinâ€“Barr virus replication is associated with XBP1 activation and early-onset post-transplant lymphoproliferative disorders with prognostic implications. Modern Pathology, 2014, 27, 1599-1611. | 2.9 | 22 |
| 278 | The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica, 2014, 99, 873-880. | 1.7 | 32 |
| 279 | Loss of signalling via GÎ±13 in germinal centre B-cell-derived lymphoma. Nature, 2014, 516, 254-258. | 13.7 | 253 |
| 280 | Assessment of SOX11 Expression in Routine Lymphoma Tissue Sections. American Journal of Surgical Pathology, 2014, 38, 86-93. | 2.1 | 58 |
| 281 | Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia, 2014, 28, 2049-2059. | 3.3 | 91 |
| 282 | Aging society and gerontechnology: A solution for an independent living?. Journal of Nutrition, Health and Aging, 2014, 18, 97-112. | 1.5 | 91 |
| 283 | Monoclonal B cell lymphocytosis and â€œin situâ€•lymphoma. Seminars in Cancer Biology, 2014, 24, 3-14. | 4.3 | 37 |
| 284 | Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nature Genetics, 2014, 46, 166-170. | 9.4 | 534 |
| 285 | Essential Role of the Linear Ubiquitin Chain Assembly Complex in Lymphoma Revealed by Rare Germline Polymorphisms. Cancer Discovery, 2014, 4, 480-493. | 7.7 | 130 |
| 286 | Unlocking New Therapeutic Targets and Resistance Mechanisms in Mantle Cell Lymphoma. Cancer Cell, 2014, 25, 7-9. | 7.7 | 17 |
| 287 | Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia. Genome Research, 2014, 24, 212-226. | 2.4 | 175 |
| 288 | Comprehensive characterization of complex structural variations in cancer by directly comparing genome sequence reads. Nature Biotechnology, 2014, 32, 1106-1112. | 9.4 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 289 | Recurrent mutations ofNOTCHgenes in follicular lymphoma identify a distinctive subset of tumours. Journal of Pathology, 2014, 234, 423-430. | 2.1 | 59 |
| 290 | Disruption of Follicular Dendritic Cellsâ€“Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib). Clinical Cancer Research, 2014, 20, 3458-3471. | 3.2 | 24 |
| 291 | Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood, 2014, 123, 3790-3796. | 0.6 | 97 |
| 292 | BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma. Human Pathology, 2014, 45, 2144-2153. | 1.1 | 34 |
| 293 | Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood, 2014, 123, 1214-1217. | 0.6 | 518 |
| 294 | Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption. Haematologica, 2014, 99, e231-e234. | 1.7 | 33 |
| 295 | Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood, 2014, 123, 1681-1690. | 0.6 | 110 |
| 296 | Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. Blood, 2014, 123, 2915-2923. | 0.6 | 435 |
| 297 | SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood, 2014, 124, 2235-2247. | 0.6 | 94 |
| 298 | Novel Putative Driver Gene Mutations in Chronic Lymphocytic Leukemia (CLL): Results from a Combined Analysis of Whole-Exome Sequencing of 262 Primary CLL Samples. Blood, 2014, 124, 1952-1952. | 0.6 | 4 |
| 299 | Accurate Diagnosis of Aggressive B Cell Non-Hodgkin Lymphomas Using Gene Expression Profiling of Formalin-Fixed, Paraffin-Embedded Tissues. Blood, 2014, 124, 3016-3016. | 0.6 | 10 |
| 300 | Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activity in CLL and hampers Leukemia-Microenvironment Interactions. Blood, 2014, 124, 4680-4680. | 0.6 | 5 |
| 301 | Dual PI3K/mTOR inhibition is required to effectively impair microenvironment survival signals in mantle cell lymphoma. Oncotarget, 2014, 5, 6788-6800. | 0.8 | 32 |
| 302 | Abstract 1691: Synergistic anti-tumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. , 2014, , . | | 1 |
| 303 | How Many Ontogenetic Roads to Mantle-Cell Lymphoma? Immunogenetic and Immunohistochemical Evidence. Blood, 2014, 124, 3005-3005. | 0.6 | 0 |
| 304 | Subset-Specific Spectra of Recurrent Gene Mutations in Chronic Lymphocytic Leukemia with Stereotyped B-Cell Receptors. Blood, 2014, 124, 3320-3320. | 0.6 | 6 |
| 305 | Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases. Blood, 2014, 124, 1677-1677. | 0.6 | 4 |
| 306 | Cell-of-Origin Subtype Classification of Diffuse Large B-Cell Lymphoma Using the Lymph2Cx Assay Retains Relevance in the Context of BCL2 and MYC Expression Status. Blood, 2014, 124, 1667-1667. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 307 | Whole-Genome DNA Methylation Analysis of Mantle Cell Lymphoma: Biological and Clinical Implications. Blood, 2014, 124, 3563-3563. | 0.6 | 0 |
| 308 | Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia. Leukemia, 2013, 27, 1600-1603. | 3.3 | 28 |
| 309 | The genomic landscape of chronic lymphocytic leukemia: clinical implications. BMC Medicine, 2013, 11, 124. | 2.3 | 35 |
| 310 | Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421. | 13.7 | 8,060 |
| 311 | Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: Review of 5,654 patients with an evaluable karyotype. Genes Chromosomes and Cancer, 2013, 52, 753-763. | 1.5 | 15 |
| 312 | Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. Journal of Clinical Oncology, 2013, 31, 4520-4528. | 0.8 | 113 |
| 313 | Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood, 2013, 122, 3884-3891. | 0.6 | 188 |
| 314 | The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells. Haematologica, 2013, 98, 1739-1747. | 1.7 | 39 |
| 315 | PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. Blood, 2013, 122, 2683-2693. | 0.6 | 98 |
| 316 | Recurrent Gene Mutations in CLL. Advances in Experimental Medicine and Biology, 2013, 792, 87-107. | 0.8 | 8 |
| 317 | Next-Generation Sequencing in Chronic Lymphocytic Leukemia. Seminars in Hematology, 2013, 50, 286-295. | 1.8 | 16 |
| 318 | Clonal evolution in chronic lymphocytic leukemia: Analysis of correlations with IGHV mutational status, NOTCH1 mutations and clinical significance. Genes Chromosomes and Cancer, 2013, 52, 920-927. | 1.5 | 15 |
| 319 | Intestinal Î³Î´ T-cell lymphomas are most frequently of type II enteropathy-associated T-cell type. Human Pathology, 2013, 44, 1131-1145. | 1.1 | 19 |
| 320 | ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Modern Pathology, 2013, 26, 1329-1337. | 2.9 | 50 |
| 321 | Genetic sequencing studies in Burkittâ€™s lymphoma: what can we learn about tumorigenesis?. Expert Review of Hematology, 2013, 6, 219-221. | 1.0 | 0 |
| 322 | Addition of Rituximab to Chlorambucil Produces Superior Event-Free Survival in the Treatment of Patients With Extranodal Marginal-Zone B-Cell Lymphoma: 5-Year Analysis of the IELSG-19 Randomized Study. Journal of Clinical Oncology, 2013, 31, 565-572. | 0.8 | 198 |
| 323 | ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma. Annals of Oncology, 2013, 24, 857-877. | 0.6 | 268 |
| 324 | POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 526-530. | 9.4 | 236 |

| # | Article | IF | Citations |
|---|---|---|---|
| 325 | ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). Annals of Oncology, 2013, 24, 561-576. | 0.6 | 193 |
| 326 | Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma. Clinical Cancer Research, 2013, 19, 586-597. | 3.2 | 24 |
| 327 | microRNA Expression Profiles Identify Subtypes of Mantle Cell Lymphoma with Different Clinicobiological Characteristics. Clinical Cancer Research, 2013, 19, 3121-3129. | 3.2 | 35 |
| 328 | Refining the Diagnosis and Prognostic Categorization of Acute Myeloid Leukemia Patients with an Integrated Use of Cytogenetic and Molecular Studies. Acta Haematologica, 2013, 129, 65-71. | 0.7 | 3 |
| 329 | Whole genome profiling and other high throughput technologies in lymphoid neoplasmsâ€"current contributions and future hopes. Modern Pathology, 2013, 26, S97-S110. | 2.9 | 17 |
| 330 | Early neoplastic lymphoid lesions. Seminars in Diagnostic Pathology, 2013, 30, 146-155. | 1.0 | 7 |
| 331 | Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nature Genetics, 2013, 45, 868-876. | 9.4 | 179 |
| 332 | NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia, 2013, 27, 1100-1106. | 3.3 | 167 |
| 333 | Genomeâ€wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features. International Journal of Cancer, 2013, 133, 2852-2863. | 2.3 | 15 |
| 334 | Clinical practice guidelines for diagnosis, treatment, and follow-up of patients with mantle cell lymphoma. Recommendations from the GEL/TAMO Spanish Cooperative Group. Annals of Hematology, 2013, 92, 1151-1179. | 0.8 | 22 |
| 335 | EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood, 2013, 122, 3165-3168. | 0.6 | 274 |
| 336 | MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica, 2013, 98, 1554-1562. | 1.7 | 196 |
| 337 | Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Hematology American Society of Hematology Education Program, 2013, 2013, 575-583. | 0.9 | 46 |
| 338 | Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 18250-18255. | 3.3 | 488 |
| 339 | Genetic and epigenetic basis of chronic lymphocytic leukemia. Current Opinion in Hematology, 2013, 20, 362-368. | 1.2 | 34 |
| 340 | Related F-box proteins control cell death in Caenorhabditis elegans and human lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 3943-3948. | 3.3 | 57 |
| 341 | Functional analysis of sucraseâ€"isomaltase mutations from chronic lymphocytic leukemia patients. Human Molecular Genetics, 2013, 22, 2273-2282. | 1.4 | 25 |
| 342 | Sporadic and reversible chromothripsis in chronic lymphocytic leukemia revealed by longitudinal genomic analysis. Leukemia, 2013, 27, 2376-2379. | 3.3 | 29 |

| # | Article | IF | Citations |
|---|---|---|---|
| 343 | Colorimetric In Situ Hybridization Identifies MYC Gene Signal Clusters Correlating With Increased Copy Number, mRNA, and Protein in Diffuse Large B-Cell Lymphoma. American Journal of Clinical Pathology, 2013, 139, 242-254. | 0.4 | 29 |
| 344 | SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood, 2013, 121, 2175-2185. | 0.6 | 129 |
| 345 | CCND2 rearrangements are the most frequent genetic events in cyclin D1â˜ mantle cell lymphoma. Blood, 2013, 121, 1394-1402. | 0.6 | 183 |
| 346 | Plasmablastic Transformation of Low-grade B-cell Lymphomas. American Journal of Surgical Pathology, 2013, 37, 272-281. | 2.1 | 59 |
| 347 | SOX11 Regulates Angiogenesis In Mantle Cell Lymphoma. Blood, 2013, 122, 246-246. | 0.6 | 1 |
| 348 | Follicular Dendrytic Cells Deliver Angiogenesis Signaling To Follicular Lymphoma Cells That Is Hampered By The Pan-PI3K Inhibitor NVP-BKM120. Blood, 2013, 122, 3072-3072. | 0.6 | 2 |
| 349 | Daratumumab, a Novel Human Anti-CD38 Monoclonal antibody shows Anti-Tumor Activity In Mouse Models Of MCL, FL and CLL. Blood, 2013, 122, 378-378. | 0.6 | 5 |
| 350 | Differential Distribution Of Recurrent Gene Mutations In Subsets Of Chronic Lymphocytic Leukemia Patients With Stereotyped B-Cell Receptors: Results From A Multicenter Project Of The European Research Initiative On CLL In A Series Of 2482 Cases. Blood, 2013, 122, 4113-4113. | 0.6 | 1 |
| 351 | Activating Mutations In Fyn Kinase In Peripheral T-Cell Lymphomas. Blood, 2013, 122, 811-811. | 0.6 | 3 |
| 352 | Recurrent Rhoa Mutations In Peripheral T-Cell Lymphoma. Blood, 2013, 122, 846-846. | 0.6 | 1 |
| 353 | The World Health Organization Classification of Lymphoid Neoplasms. , 2013, , 1-34. | | 0 |
| 354 | Novel Gene Mutations In Chronic Lymphocytic Leukemia: Prevalence and Clinical Implications In A Series Of 3185 Cases - Initial Results From The European Research Initiative On CLL. Blood, 2013, 122, 1614-1614. | 0.6 | 0 |
| 355 | Recurrent Mutations Of NOTCH Genes In Follicular Lymphoma. Blood, 2013, 122, 4253-4253. | 0.6 | 4 |
| 356 | Determining Cell-Of-Origin Subtypes In Diffuse Large B-Cell Lymphoma Using Gene Expression Profiling On Formalin-Fixed Paraffin-Embedded Tissue â€“ An L.L.M.P.P. Project. Blood, 2013, 122, 73-73. | 0.6 | 0 |
| 357 | Counteracting Autophagy Overcomes Resistance to Everolimus in Mantle Cell Lymphoma. Clinical Cancer Research, 2012, 18, 5278-5289. | 3.2 | 58 |
| 358 | Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. Journal of Clinical Oncology, 2012, 30, 3452-3459. | 0.8 | 824 |
| 359 | Molecular Subsets of Mantle Cell Lymphoma Defined by the IGHV Mutational Status and SOX11 Expression Have Distinct Biologic and Clinical Features. Cancer Research, 2012, 72, 5307-5316. | 0.4 | 231 |
| 360 | Increased tumor cell proliferation in mantle cell lymphoma is associated with elevated insulin-like growth factor 2 mRNA-binding protein 3 expression. Modern Pathology, 2012, 25, 1227-1235. | 2.9 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 361 | Association of NOS2 and potential effect of VEGF, IL6, CCL2 and IL1RN polymorphisms and haplotypes on susceptibility to GCA--a simultaneous study of 130 potentially functional SNPs in 14 candidate genes. Rheumatology, 2012, 51, 841-851. | 0.9 | 38 |
| 362 | Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells. Leukemia, 2012, 26, 1429-1432. | 3.3 | 17 |
| 363 | Extranodal NK/T-cell Lymphoma, Nasal Type, Includes Cases of Natural Killer Cell and Î±Î², Î³Î´, and Î±Î²/Î³Î´ T-cell Origin. American Journal of Surgical Pathology, 2012, 36, 481-499. | 2.1 | 190 |
| 364 | Primary Bone Marrow Lymphoma. American Journal of Surgical Pathology, 2012, 36, 296-304. | 2.1 | 59 |
| 365 | In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior. Haematologica, 2012, 97, 270-278. | 1.7 | 146 |
| 366 | 797 The Novel PI3K Kinase Inhibitor NVP-BKM120 Shows in Vitro and in Vivo Efficacy in Follicular Lymphoma by Disrupting Microenvironment Survival Signaling. European Journal of Cancer, 2012, 48, S190. | 1.3 | 0 |
| 367 | 850 Autophagy Inhibition Sensitizes Mantle Cell Lymphoma Cells to Everolimus. European Journal of Cancer, 2012, 48, S204. | 1.3 | 0 |
| 368 | 1046 Sorafenib Inhibits Cell Migration and Stroma-mediated Bortezomib Resistance by Interfering BCR Signaling and Protein Translation in Mantle Cell Lymphoma. European Journal of Cancer, 2012, 48, S252. | 1.3 | 0 |
| 369 | Molecular distinctions between pediatric and adult mature B-cell non-Hodgkin lymphomas identified through genomic profiling. Blood, 2012, 119, 3757-3766. | 0.6 | 72 |
| 370 | A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma. Blood, 2012, 120, 2290-2296. | 0.6 | 53 |
| 371 | Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications. Human Pathology, 2012, 43, 467-480. | 1.1 | 20 |
| 372 | Epigenomic analysis detects widespread gene-body DNA hypomethylation in chronic lymphocytic leukemia. Nature Genetics, 2012, 44, 1236-1242. | 9.4 | 525 |
| 373 | Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature, 2012, 490, 116-120. | 13.7 | 759 |
| 374 | New pathogenic mechanisms in Burkitt lymphoma. Nature Genetics, 2012, 44, 1288-1289. | 9.4 | 23 |
| 375 | Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia, 2012, 26, 1895-1898. | 3.3 | 141 |
| 376 | Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics, 2012, 44, 47-52. | 9.4 | 893 |
| 377 | Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis. Blood, 2012, 119, 4939-4948. | 0.6 | 97 |
| 378 | Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes and Cancer, 2012, 51, 881-889. | 1.5 | 57 |

| # | Article | IF | Citations |
|---|---|---|---|
| 379 | NOTCH1 mutations in chronic lymphocytic leukemia with trisomy 12. Genes Chromosomes and Cancer, 2012, 51, 1064-1065. | 1.5 | 0 |
| 380 | BLUEPRINT to decode the epigenetic signature written in blood. Nature Biotechnology, 2012, 30, 224-226. | 9.4 | 323 |
| 381 | A new genetic abnormality leading to TP53 gene deletion in chronic lymphocytic leukaemia. British Journal of Haematology, 2012, 156, 612-618. | 1.2 | 7 |
| 382 | SOX11 is useful in differentiating cyclin D1â€positive diffuse large Bâ€cell lymphoma from mantle cell lymphoma. Histopathology, 2012, 61, 685-693. | 1.6 | 41 |
| 383 | Abstract 1942: Activity of lenalidomidein vitroandin vivomodels of bortezomib-resistant mantle cell lymphoma involving the modulation of c-myc/p27 axis. , 2012, , . | | 1 |
| 384 | Molecular pathogenesis of mantle cell lymphoma. Journal of Clinical Investigation, 2012, 122, 3416-3423. | 3.9 | 325 |
| 385 | Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Nonâ€“Hodgkin Lymphoma. Blood, 2012, 120, 3935-3935. | 0.6 | 6 |
| 386 | Gene Expression Signatures That Delineate Biologic and Prognostic Subgroups in Peripheral T-Cell Lymphoma. Blood, 2012, 120, 679-679. | 0.6 | 2 |
| 387 | High Incidence of EZH2 Mutations with Variable Mutation Load in Follicular Lymphoma and Its Consequences for EZH2 Targeted Therapy. Blood, 2012, 120, 545-545. | 0.6 | 0 |
| 388 | High Expression of Activation-Induced Cytidine Deaminase and in Vivo Class Switch Recombination in Mantle Cell Lymphoma: Further Support for Antigen Involvement in Lymphomagenesis. Blood, 2012, 120, 1538-1538. | 0.6 | 0 |
| 389 | Genetic Abnormalities in Follicular Lymphoma and Transformed Follicular Lymphoma.. Blood, 2012, 120, 2648-2648. | 0.6 | 0 |
| 390 | The Multi-Kinase Inhibitor Sorafenib Blocks Migration, BCR Survival Signals, Protein Translation and Stroma-Mediated Bortezomib Resistance in Mantle Cell Lymphoma. Blood, 2012, 120, 1647-1647. | 0.6 | 5 |
| 391 | Is there a role for antigen selection in mantle cell lymphoma? Immunogenetic support from a series of 807 cases. Blood, 2011, 118, 3088-3095. | 0.6 | 149 |
| 392 | Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature, 2011, 475, 101-105. | 13.7 | 1,364 |
| 393 | The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood, 2011, 117, 5019-5032. | 0.6 | 1,681 |
| 394 | The Expression of the Endoplasmic Reticulum Stress Sensor BiP/GRP78 Predicts Response to Chemotherapy and Determines the Efficacy of Proteasome Inhibitors in Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2011, 179, 2601-2610. | 1.9 | 57 |
| 395 | Molecular Pathogenesis of Mantle Cell Lymphoma: New Perspectives and Challenges With Clinical Implications. Seminars in Hematology, 2011, 48, 155-165. | 1.8 | 16 |
| 396 | Identification of Methylated Genes Associated with Aggressive Clinicopathological Features in Mantle Cell Lymphoma. PLoS ONE, 2011, 6, e19736. | 1.1 | 32 |

| # | Article | IF | Citations |
|---|---|---|---|
| 397 | Epigenetic Activation of SOX11 in Lymphoid Neoplasms by Histone Modifications. PLoS ONE, 2011, 6, e21382. | 1.1 | 38 |
| 398 | Molecular Characteristics of Mantle Cell Lymphoma Presenting With Clonal Plasma Cell Component. American Journal of Surgical Pathology, 2011, 35, 177-189. | 2.1 | 23 |
| 399 | Nonhepatosplenic Î³Î´ T-cell Lymphomas Represent a Spectrum of Aggressive Cytotoxic T-cell Lymphomas With a Mainly Extranodal Presentation. American Journal of Surgical Pathology, 2011, 35, 1214-1225. | 2.1 | 120 |
| 400 | The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood, 2011, 117, 1270-1279. | 0.6 | 102 |
| 401 | Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood, 2011, 117, 4836-4843. | 0.6 | 280 |
| 402 | Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. Blood, 2011, 117, 7070-7078. | 0.6 | 168 |
| 403 | MicroRNA profiles of t(14;18)â€“negative follicular lymphoma support a late germinal center B-cell phenotype. Blood, 2011, 118, 5550-5558. | 0.6 | 77 |
| 404 | High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy. Haematologica, 2011, 96, 996-1001. | 1.7 | 100 |
| 405 | Initial features and outcome of cutaneous and nonâ€cutaneous primary extranodal follicular lymphoma. British Journal of Haematology, 2011, 153, 334-340. | 1.2 | 18 |
| 406 | Oncogenically active MYD88 mutations in human lymphoma. Nature, 2011, 470, 115-119. | 13.7 | 1,292 |
| 407 | The complex landscape of genetic alterations in mantle cell lymphoma. Seminars in Cancer Biology, 2011, 21, 322-334. | 4.3 | 100 |
| 408 | A putative â€œhepitypeâ€• in the ATM gene associated with chronic lymphocytic leukemia risk. Genes Chromosomes and Cancer, 2011, 50, 887-895. | 1.5 | 5 |
| 409 | The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. American Journal of Clinical Pathology, 2011, 135, 54-61. | 0.4 | 71 |
| 410 | Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. Journal of Clinical Oncology, 2011, 29, 200-207. | 0.8 | 426 |
| 411 | Comparison of four prognostic scores in peripheral T-cell lymphoma. Annals of Oncology, 2011, 22, 397-404. | 0.6 | 84 |
| 412 | II. New perspectives and challenges in the understanding of mantle cell lymphoma. Annals of Oncology, 2011, 22, iv32-iv35. | 0.6 | 5 |
| 413 | Vorinostat-Induced Apoptosis in Mantle Cell Lymphoma Is Mediated by Acetylation of Proapoptotic BH3-Only Gene Promoters. Clinical Cancer Research, 2011, 17, 3956-3968. | 3.2 | 76 |
| 414 | Accurate Classification of Diffuse Large B-Cell Lymphoma into Germinal Center and Activated B-Cell Subtypes Using a Nuclease Protection Assay on Formalin-Fixed, Paraffin-Embedded Tissues. Clinical Cancer Research, 2011, 17, 3727-3732. | 3.2 | 68 |

| # | Article | IF | Citations |
|---|---|---|---|
| 415 | BCL2 Predicts Survival in Germinal Center B-cellâ€“like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab. Clinical Cancer Research, 2011, 17, 7785-7795. | 3.2 | 152 |
| 416 | Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood, 2011, 117, 3402-3408. | 0.6 | 376 |
| 417 | Normal Lymphoid Organs and Tissues. , 2011, , 97-117. | | 3 |
| 418 | Mantle Cell Lymphoma. , 2011, , 333-348. | | 8 |
| 419 | Recurrent Oncogenic Mutations in CCND3 in Aggressive Lymphomas. Blood, 2011, 118, 435-435. | 0.6 | 0 |
| 420 | BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). Blood, 2011, 118, 2634-2634. | 0.6 | 0 |
| 421 | FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type. Histology and Histopathology, 2011, 26, 213-21. | 0.5 | 16 |
| 422 | Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling. Blood, 2010, 116, 953-961. | 0.6 | 122 |
| 423 | Response to lenalidomide in patients with myelodysplastic syndrome with deletion 5q: clinical and cytogenetic analysis of a single centre series. Annals of Hematology, 2010, 89, 1069-1070. | 0.8 | 0 |
| 424 | Cooperative Epigenetic Modulation by Cancer Amplicon Genes. Cancer Cell, 2010, 18, 590-605. | 7.7 | 263 |
| 425 | Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes and Cancer, 2010, 49, 439-451. | 1.5 | 68 |
| 426 | Do we need to do fluorescence in situ hybridization analysis in myelodysplastic syndromes as often as we do?. Leukemia Research, 2010, 34, 1437-1441. | 0.4 | 27 |
| 427 | Verification that common variation at 2q37.1, 6p25.3, 11q24.1, 15q23, and 19q13.32 influences chronic lymphocytic leukaemia risk. British Journal of Haematology, 2010, 150, 473-479. | 1.2 | 34 |
| 428 | Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature, 2010, 463, 88-92. | 13.7 | 1,402 |
| 429 | International network of cancer genome projects. Nature, 2010, 464, 993-998. | 13.7 | 2,114 |
| 430 | Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. Nature Genetics, 2010, 42, 132-136. | 9.4 | 223 |
| 431 | IG/MYC Rearrangements are the Main Cytogenetic Alteration in Plasmablastic Lymphomas. American Journal of Surgical Pathology, 2010, 34, 1686-1694. | 2.1 | 251 |
| 432 | Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior. Haematologica, 2010, 95, 1526-1533. | 1.7 | 158 |

| # | Article | IF | Citations |
|---|---|---|---|
| 433 | 195 Molecular bases of everolimus antiproliferative activity in mantle cell lymphoma. European Journal of Cancer, Supplement, 2010, 8, 65. | 2.2 | 0 |
| 434 | Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma. New England Journal of Medicine, 2010, 362, 875-885. | 13.9 | 1,141 |
| 435 | Clinico-biological characterization and outcome of primary nodal and extranodal diffuse large B-cell lymphoma in the rituximab era. Leukemia and Lymphoma, 2010, 51, 1225-1232. | 0.6 | 36 |
| 436 | Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma. Cancer Research, 2010, 70, 1408-1418. | 0.4 | 429 |
| 437 | Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. Blood, 2010, 116, 432-432. | 0.6 | 5 |
| 438 | Concurrent BCL2 and MYC Protein Expression by Immunohistochemistry Determines Clinical Outcome In DLBCL Patients Treated with R-CHOP. Blood, 2010, 116, 2005-2005. | 0.6 | 2 |
| 439 | The Nucleoside Analogue Acadesine Exerts Antitumoral Activity and Cooperates with Conventional Agents In In Vitro and In Vivo Models of Mantle Cell Lymphoma. Blood, 2010, 116, 3918-3918. | 0.6 | 0 |
| 440 | Applicability of Different Immunohistochemistry Algorithms to Assess Gene Expression Profile In Patients with Diffuse Large B-Cell Lymphoma. Blood, 2010, 116, 4134-4134. | 0.6 | 0 |
| 441 | Intravascular lymphoma occurring in patients with other non-Hodgkin lymphomas. Clinical Advances in Hematology and Oncology, 2010, 8, 641-2. | 0.3 | 5 |
| 442 | CIITA or RFX coding region loss of function mutations occur rarely in diffuse large B-cell lymphoma cases and cell lines with low levels of major histocompatibility complex class II expression. Haematologica, 2009, 94, 596-598. | 1.7 | 18 |
| 443 | MicroRNA Expression, Chromosomal Alterations, and Immunoglobulin Variable Heavy Chain Hypermutations in Mantle Cell Lymphomas. Cancer Research, 2009, 69, 7071-7078. | 0.4 | 78 |
| 444 | SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica, 2009, 94, 1555-1562. | 1.7 | 345 |
| 445 | p65 Activity and ZAP-70 Status Predict the Sensitivity of Chronic Lymphocytic Leukemia Cells to the Selective IÎºB Kinase Inhibitor BMS-345541. Clinical Cancer Research, 2009, 15, 2767-2776. | 3.2 | 31 |
| 446 | Ki-67 as a prognostic marker in mantle cell lymphomaâ€"consensus guidelines of the pathology panel of the European MCL Network. Journal of Hematopathology, 2009, 2, 103-111. | 0.2 | 149 |
| 447 | Array-based DNA methylation profiling in follicular lymphoma. Leukemia, 2009, 23, 1858-1866. | 3.3 | 65 |
| 448 | Most primary adrenal lymphomas are diffuse large B-cell lymphomas with non-germinal center B-cell phenotype, BCL6 gene rearrangement and poor prognosis. Modern Pathology, 2009, 22, 1210-1217. | 2.9 | 70 |
| 449 | Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood, 2009, 114, 826-834. | 0.6 | 177 |
| 450 | High Numbers of Tumor-Infiltrating Programmed Cell Death 1â€"Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma. Journal of Clinical Oncology, 2009, 27, 1470-1476. | 0.8 | 273 |

| # | Article | IF | Citations |
|---|---|---|---|
| 451 | Decreased major histocompatibility complex class II expression in diffuse large B-cell lymphoma does not correlate with CpG methylation of class II transactivator promoters III and IV. Leukemia and Lymphoma, 2009, 50, 1875-1878. | 0.6 | 9 |
| 452 | A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy. Clinical Cancer Research, 2009, 15, 5494-5502. | 3.2 | 577 |
| 453 | EML4-ALK Rearrangement in Non-Small Cell Lung Cancer and Non-Tumor Lung Tissues. American Journal of Pathology, 2009, 174, 661-670. | 1.9 | 301 |
| 454 | Activation of the Endoplasmic Reticulum Stress-Associated Transcription Factor X Box-Binding Protein-1 Occurs in a Subset of Normal Germinal-Center B Cells and in Aggressive B-Cell Lymphomas with Prognostic Implications. American Journal of Pathology, 2009, 174, 2337-2346. | 1.9 | 32 |
| 455 | Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital ClÃnic of Barcelona experience. Blood, 2009, 114, 2044-2050. | 0.6 | 132 |
| 456 | Primary Cutaneous CD4+ Small/Medium-sized Pleomorphic T-cell Lymphoma Expresses Follicular T-cell Markers. American Journal of Surgical Pathology, 2009, 33, 81-90. | 2.1 | 226 |
| 457 | Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood, 2009, 113, 3059-3069. | 0.6 | 162 |
| 458 | Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation. Blood, 2009, 113, 2298-2301. | 0.6 | 75 |
| 459 | Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM. Blood, 2009, 114, 1563-1575. | 0.6 | 50 |
| 460 | Sequence-Based Evidence for Antigen Selection in Mantle Cell Lymphoma: Remarkable Immunoglobulin Gene Repertoire Biases, Stereotyped Antigen-Binding Sites and Recurrent Hypermutations in Certain Subsets.. Blood, 2009, 114, 1933-1933. | 0.6 | 2 |
| 461 | T-Cell Subpopulations Quantified by Flow Cytometry in Lymph Node Cell Suspensions Identify a Group of Patients with Follicular Lymphoma with Good Prognosis.. Blood, 2009, 114, 1945-1945. | 0.6 | 0 |
| 462 | The Expression of the ER Stress Sensor GRP78/Bip Is a Target of R-CHOP and Bortezomib Treatments in DLBCL with Prognostic Value. A Rationale for the Use of Proteasome Inhibitors in DLBCL Patients.. Blood, 2009, 114, 3734-3734. | 0.6 | 0 |
| 463 | Conventional and Molecular Cytogenetic Responses in Patients with Myelodysplastic Syndrome (MDS) with Deletion 5q Treated with Lenalidomide.. Blood, 2009, 114, 1746-1746. | 0.6 | 1 |
| 464 | Chromosomal Alterations in Gene Expression-Defined Pediatric Aggressive B-Cell Non-Hodgkin Lymphoma (B-NHL).. Blood, 2009, 114, 2922-2922. | 0.6 | 0 |
| 465 | High Microvascular Density Correlates with Poor Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Rituximab Plus Chemotherapy (R-CT).. Blood, 2009, 114, 1948-1948. | 0.6 | 0 |
| 466 | FOXP1 status in splenic marginal zone lymphoma: a fluorescence in situ hybridization and immunohistochemistry approach. Histology and Histopathology, 2009, 24, 1399-404. | 0.5 | 2 |
| 467 | The follicular lymphoma microenvironment: From tumor cell to host immunity. Current Hematologic Malignancy Reports, 2008, 3, 179-186. | 1.2 | 6 |
| 468 | Multiple recurrent chromosomal breakpoints in mantle cell lymphoma revealed by a combination of molecular cytogenetic techniques. Genes Chromosomes and Cancer, 2008, 47, 1086-1097. | 1.5 | 28 |

| # | Article | IF | Citations |
|---|---|---|---|
| 469 | New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY). Leukemia Research, 2008, 32, 727-736. | 0.4 | 20 |
| 470 | BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 2008, 22, 1712-1720. | 3.3 | 84 |
| 471 | Genomic profiling reveals different genetic aberrations in systemic ALKâ€positive and ALKâ€negative anaplastic large cell lymphomas. British Journal of Haematology, 2008, 140, 516-526. | 1.2 | 145 |
| 472 | Advances in the understanding of mantle cell lymphoma. British Journal of Haematology, 2008, 142, 149-165. | 1.2 | 154 |
| 473 | Integrated genomic and expression profiling in mantle cell lymphoma: identification of geneâ€dosage regulated candidate genes. British Journal of Haematology, 2008, 143, 210-221. | 1.2 | 27 |
| 474 | Co-regulation analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer. BMC Cancer, 2008, 8, 315. | 1.1 | 10 |
| 475 | Osteopontin and Î±vÎ²3 integrin expression in the endometrium of infertile and fertile women. Reproductive BioMedicine Online, 2008, 16, 808-816. | 1.1 | 27 |
| 476 | Increased messenger ribonucleic acid expression of the cyclin-dependent kinase inhibitor p27Kip1 in cleavage-stage human embryos exhibiting developmental arrest. Fertility and Sterility, 2008, 89, 1557-1562. | 0.5 | 4 |
| 477 | Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma. Science, 2008, 319, 1676-1679. | 6.0 | 784 |
| 478 | Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 13520-13525. | 3.3 | 868 |
| 479 | Genetic Variants in Apoptosis and Immunoregulation-Related Genes Are Associated with Risk of Chronic Lymphocytic Leukemia. Cancer Research, 2008, 68, 10178-10186. | 0.4 | 67 |
| 480 | Stromal Gene Signatures in Large-B-Cell Lymphomas. New England Journal of Medicine, 2008, 359, 2313-2323. | 13.9 | 1,564 |
| 481 | Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. Journal of Clinical Oncology, 2008, 26, 4966-4972. | 0.8 | 101 |
| 482 | Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling. Clinical Cancer Research, 2008, 14, 6907-6915. | 3.2 | 69 |
| 483 | Chromosomal alterations detected by comparative genomic hybridization in subgroups of gene expression-defined Burkitt's lymphoma. Haematologica, 2008, 93, 1327-1334. | 1.7 | 80 |
| 484 | Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells. Haematologica, 2008, 93, 1843-1851. | 1.7 | 20 |
| 485 | Primary Cutaneous Small/Medium CD4<sup>+</sup> T-Cell Lymphomas: A Heterogeneous Group of Tumors With Different Clinicopathologic Features and Outcome. Journal of Clinical Oncology, 2008, 26, 3364-3371. | 0.8 | 163 |
| 486 | Central nervous system involvement in mantle cell lymphoma. Annals of Oncology, 2008, 19, 135-141. | 0.6 | 89 |

| # | Article | IF | Citations |
|---|---|---|---|
| 487 | Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study. Blood, 2008, 112, 3088-3098. | 0.6 | 173 |
| 488 | Gene expression predicts overall survival in paraffin-embedded tissues of diffuse large B-cell lymphoma treated with R-CHOP. Blood, 2008, 112, 3425-3433. | 0.6 | 130 |
| 489 | The presence of TP53 mutation at diagnosis of follicular lymphoma identifies a high-risk group of patients with shortened time to disease progression and poorer overall survival. Blood, 2008, 112, 3126-3129. | 0.6 | 112 |
| 490 | High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica, 2008, 93, 207-214. | 1.7 | 24 |
| 491 | Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia. Haematologica, 2008, 93, 132-136. | 1.7 | 17 |
| 492 | Secondary genomic alterations in non-Hodgkin's lymphomas: tumor-specific profiles with impact on clinical behavior. Haematologica, 2008, 93, 641-645. | 1.7 | 16 |
| 493 | Changes in the Natural History, Treatment Modalities, and Survival Patterns in Patients with Chronic Lymphocytic Leukemia (CLL) from 1980 to 2008. The Hospital Clinic of Barcelona Experience. Blood, 2008, 112, 48-48. | 0.6 | 1 |
| 494 | Molecular Signatures Implicate Innate Immune Cells, Fibrosis, and Angiogenesis in Survival Following R-CHOP Treatment of Diffuse Large B Cell Lymphoma. Blood, 2008, 112, 475-475. | 0.6 | 1 |
| 495 | Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics. Blood, 2008, 112, 2522-2522. | 0.6 | 0 |
| 496 | Genome-Wide Expression Profiling Predicts Treatment Outcome in Classical Hodgkin Lymphoma. Blood, 2008, 112, 520-520. | 0.6 | 0 |
| 497 | No Benefit from Rituximab Containing Regimens in Patients with Primary Extranodal Diffuse Large B-Cell Lymphoma. Blood, 2008, 112, 3615-3615. | 0.6 | 5 |
| 498 | Selective Inhibition of ÎºB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level. Journal of Immunology, 2007, 178, 1923-1930. | 0.4 | 81 |
| 499 | Specific Secondary Genetic Alterations in Mantle Cell Lymphoma Provide Prognostic Information Independent of the Gene Expressionâ€"Based Proliferation Signature. Journal of Clinical Oncology, 2007, 25, 1216-1222. | 0.8 | 166 |
| 500 | Redistribution of FOXP3-Positive Regulatory T Cells From Lymphoid Tissues to Peripheral Blood in HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2007, 46, 529-537. | 0.9 | 28 |
| 501 | Genetics of Carney Triad: Recurrent Losses at Chromosome 1 but Lack of Germline Mutations in Genes Associated with Paragangliomas and Gastrointestinal Stromal Tumors. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2938-2943. | 1.8 | 141 |
| 502 | Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica, 2007, 92, 486-492. | 1.7 | 164 |
| 503 | Variant hairy cell leukemia without distinct nucleoli. Leukemia and Lymphoma, 2007, 48, 1050-1052. | 0.6 | 2 |
| 504 | Aberrant immunoglobulin class switch recombination and switch translocations in activated B cellâ€"like diffuse large B cell lymphoma. Journal of Experimental Medicine, 2007, 204, 633-643. | 4.2 | 176 |

| # | Article | IF | Citations |
|---|---|---|---|
| 505 | Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applicationsâ€"A Study From the Lunenburg Lymphoma Biomarker Consortium. Journal of Clinical Oncology, 2007, 25, 805-812. | 0.8 | 271 |
| 506 | The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood, 2007, 109, 4441-4449. | 0.6 | 184 |
| 507 | Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival. Blood, 2007, 109, 4599-4606. | 0.6 | 226 |
| 508 | Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood, 2007, 109, 5422-5429. | 0.6 | 76 |
| 509 | Mutations in the DNA-binding codons of TP53, which are associated with decreased expression of TRAILreceptor-2, predict for poor survival in diffuse large B-cell lymphoma. Blood, 2007, 110, 4396-4405. | 0.6 | 103 |
| 510 | Epstein-Barr Virus Negative Clonal Plasma Cell Proliferations and Lymphomas in Peripheral T-cell Lymphomas. American Journal of Surgical Pathology, 2007, 31, 1310-1322. | 2.1 | 77 |
| 511 | Cutaneous Î³/Î´ T-cell lymphoma: A histopathologic mimicker of lupus erythematosus profundus (lupus) Tj ETQq1 1 0.784314 rgBT /Ov | 0.6 | 48 |
| 512 | Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia, 2007, 21, 2332-2343. | 3.3 | 198 |
| 513 | Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives From an International Consensus Meeting. Journal of Clinical Oncology, 2007, 25, 3168-3173. | 0.8 | 449 |
| 514 | Frequent occurrence of deletions in primary mediastinal Bâ€cell lymphoma. Genes Chromosomes and Cancer, 2007, 46, 1090-1097. | 1.5 | 36 |
| 515 | Leukemic involvement is a common feature in mantle cell lymphoma. Cancer, 2007, 109, 2473-2480. | 2.0 | 82 |
| 516 | Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nature Reviews Cancer, 2007, 7, 750-762. | 12.8 | 433 |
| 517 | Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. British Journal of Haematology, 2007, 136, 286-293. | 1.2 | 142 |
| 518 | High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing. American Journal of Obstetrics and Gynecology, 2007, 197, 359.e1-359.e6. | 0.7 | 25 |
| 519 | Association of CDK4 and CCND1 mRNA overexpression in laryngeal squamous cell carcinomas occurs without CDK4 amplification. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2007, 450, 161-167. | 1.4 | 12 |
| 520 | The Purine Nucleoside Phosphorylase Inhibitor Forodesine (BCX-1777) Is a Potent Cytotoxic Agent and Has Synergistic Activity with Bendamustine in Chronic Lymphocytic Leukemia (CLL) Irrespective of ZAP-70 Levels and p53 Status.. Blood, 2007, 110, 3122-3122. | 0.6 | 10 |
| 521 | BCL-2 Phosphorylation Modulates Sensitivity to the BH3-Mimetic GX15-070 (Obatoclax) and Reduces Its Synergistic Interaction with Bortezomib in Chronic Lymphocytic Leukemia Cells.. Blood, 2007, 110, 3464-3464. | 0.6 | 1 |
| 522 | Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy.. Blood, 2007, 110, 348-348. | 0.6 | 11 |

| # | Article | IF | Citations |
|---|---|---|---|
| 523 | CARD11 as an Oncogene in Diffuse Large B Cell Lymphoma.. Blood, 2007, 110, 692-692. | 0.6 | 2 |
| 524 | Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309. Haematologica, 2007, 92, 574-575. | 1.7 | 30 |
| 525 | Follicular Lymphomas with and without Translocation t(14;18) Differ in Gene Expression Profiles and Genetic Alterations.. Blood, 2007, 110, 360-360. | 0.6 | 7 |
| 526 | SNP Array Analysis Reveals Copy Number Alterations and Uniparental Disomy in Mantle Cell Lymphomas at High Resolution.. Blood, 2007, 110, 1585-1585. | 0.6 | 0 |
| 527 | The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma. Annals of Oncology, 2006, 17, 1539-1545. | 0.6 | 107 |
| 528 | Aberrant somatic hypermutation in tumor cells of nodular-lymphocyte-predominant and classic Hodgkin lymphoma. Blood, 2006, 108, 1013-1020. | 0.6 | 75 |
| 529 | The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood, 2006, 107, 257-264. | 0.6 | 417 |
| 530 | Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood, 2006, 107, 4563-4569. | 0.6 | 130 |
| 531 | High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood, 2006, 108, 2957-2964. | 0.6 | 448 |
| 532 | p16 Overexpression Identifies HPV-positive Vulvar Squamous Cell Carcinomas. American Journal of Surgical Pathology, 2006, 30, 1347-1356. | 2.1 | 150 |
| 533 | ALK-Positive Anaplastic Large Cell Lymphoma Mimicking Nodular Sclerosis Hodgkin's Lymphoma. American Journal of Surgical Pathology, 2006, 30, 223-229. | 2.1 | 77 |
| 534 | Uterine (CD56+) Natural Killer Cells Recruitment: Association with Decidual Reaction Rather than Embryo Implantation. American Journal of Reproductive Immunology, 2006, 55, 369-377. | 1.2 | 30 |
| 535 | Update on extranodal lymphomas. Conclusions of the Workshop held by the EAHP and the SH in Thessaloniki, Greece. Histopathology, 2006, 48, 481-504. | 1.6 | 77 |
| 536 | Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leukemia Research, 2006, 30, 923-934. | 0.4 | 45 |
| 537 | Genomic platforms for cancer research: potential diagnostic and prognostic applications in clinical oncology. Clinical and Translational Oncology, 2006, 8, 161-172. | 1.2 | 6 |
| 538 | Pre- and post-conization high-risk HPV testing predicts residual/recurrent disease in patients treated for CIN 2â€“3. Gynecologic Oncology, 2006, 103, 631-636. | 0.6 | 125 |
| 539 | Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. European Journal of Haematology, 2006, 76, 58-63. | 1.1 | 36 |
| 540 | Herpes simplex and Epstein-Barr virus lymphadenitis in a patient with chronic lymphocytic leukemia treated with fludarabine. European Journal of Haematology, 2006, 77, 442-444. | 1.1 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 541 | Studies of complex Ph translocations in cases with chronic myelogenous leukemia and one with acute lymphoblastic leukemia. Cancer Genetics and Cytogenetics, 2006, 166, 89-93. | 1.0 | 12 |
| 542 | Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements. Cancer Genetics and Cytogenetics, 2006, 170, 115-120. | 1.0 | 12 |
| 543 | Mantle cell lymphoma in Taiwan: Clinicopathological and molecular study of 21 cases including one cyclin D1-negative tumor expressing cyclin D2. Pathology International, 2006, 56, 440-448. | 0.6 | 20 |
| 544 | Analysis ofAurora-A andhMPS1 mitotic kinases in mantle cell lymphoma. International Journal of Cancer, 2006, 118, 357-363. | 2.3 | 28 |
| 545 | Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability. International Journal of Cancer, 2006, 119, 2768-2774. | 2.3 | 32 |
| 546 | The Severe Gout of Holy Roman Emperor Charles V. New England Journal of Medicine, 2006, 355, 516-520. | 13.9 | 36 |
| 547 | Activation of nuclear factor-Î¤ B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocrine-Related Cancer, 2006, 13, 607-616. | 1.6 | 86 |
| 548 | ZAP-70 Expression in Normal Pro/Pre B Cells, Mature B Cells, and in B-Cell Acute Lymphoblastic Leukemia. Clinical Cancer Research, 2006, 12, 726-734. | 3.2 | 50 |
| 549 | BCL2 Expression Is a Prognostic Marker for the Activated B-Cellâ€“Like Type of Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2006, 24, 961-968. | 0.8 | 277 |
| 550 | Lack of Methylthioadenosine Phosphorylase Expression in Mantle Cell Lymphoma Is Associated with Shorter Survival: Implications for a Potential Targeted Therapy. Clinical Cancer Research, 2006, 12, 3754-3761. | 3.2 | 31 |
| 551 | Molecular Diagnosis of Burkitt's Lymphoma. New England Journal of Medicine, 2006, 354, 2431-2442. | 13.9 | 824 |
| 552 | Mutation and genomic deletion status ofataxia telangiectasia mutated(ATM) andp53confer specific gene expression profiles in mantle cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 2352-2357. | 3.3 | 138 |
| 553 | Gene Expression Profiling of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13) and MYST3-CREBBP Rearrangement Reveals a Distinctive Signature with a Specific Pattern of HOX Gene Expression. Cancer Research, 2006, 66, 6947-6954. | 0.4 | 127 |
| 554 | Aberrant Immunoglobulin Class Switch Recombination and Switch Translocations in Activated B Cell-Like Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 356-356. | 0.6 | 2 |
| 555 | ATM gene expression is associated with differentiation and angiogenesis in infiltrating breast carcinomas. Histology and Histopathology, 2006, 21, 149-56. | 0.5 | 11 |
| 556 | Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. , 2006, , 406-414. | | 0 |
| 557 | Selective Inhibition of I kappaB Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing c-FLIP Level.. Blood, 2006, 108, 258-258. | 0.6 | 0 |
| 558 | Activation of the Endoplasmic Reticulum (ER) Unfolded Protein Response (UPR) in Aggressive B-Cell Lymphomas.. Blood, 2006, 108, 2038-2038. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 559 | Activity of Bendamustine (TREANDAâ„¢) in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma Cells with Alterations in DNA Damage Response Pathway.. Blood, 2006, 108, 2510-2510. | 0.6 | 1 |
| 560 | Primary Extranodal Follicular Lymphoma: Clinicobiological Features and Outcome.. Blood, 2006, 108, 2456-2456. | 0.6 | 0 |
| 561 | Integrated CGH- and Epression Array Profiling of Mantle Cell Lymphoma.. Blood, 2006, 108, 2252-2252. | 0.6 | 0 |
| 562 | Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica, 2006, 91, 11-6. | 1.7 | 135 |
| 563 | Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica, 2006, 91, 895-902. | 1.7 | 63 |
| 564 | Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood, 2005, 106, 1831-1838. | 0.6 | 138 |
| 565 | Holes in SOCS in primary mediastinal large B-cell lymphoma. Blood, 2005, 105, 2244-2245. | 0.6 | 2 |
| 566 | Loss of major histocompatibility class II expression in non-immune-privileged site diffuse large B-cell lymphoma is highly coordinated and not due to chromosomal deletions. Blood, 2005, 107, 1101-1107. | 0.6 | 68 |
| 567 | Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood, 2005, 106, 4315-4321. | 0.6 | 330 |
| 568 | A Practical Approach to Intraoperative Evaluation of Sentinel Lymph Node Biopsy in Breast Carcinoma and Review of the Current Methods. Annals of Surgical Oncology, 2005, 12, 313-321. | 0.7 | 18 |
| 569 | Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. British Journal of Haematology, 2005, 130, 729-732. | 1.2 | 40 |
| 570 | Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. British Journal of Haematology, 2005, 131, 29-38. | 1.2 | 299 |
| 571 | Activation of nuclear factor-Î¹B in human prostate carcinogenesis and association to biochemical relapse. British Journal of Cancer, 2005, 93, 1285-1294. | 2.9 | 109 |
| 572 | Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms. Leukemia, 2005, 19, 112-117. | 3.3 | 42 |
| 573 | Differential expression of NF-Î¹B pathway genes among peripheral T-cell lymphomas. Leukemia, 2005, 19, 2254-2263. | 3.3 | 112 |
| 574 | Immunoarchitecture of lymphoid tissue in HIV-infection during antiretroviral therapy correlates with viral persistence. Modern Pathology, 2005, 18, 127-136. | 2.9 | 43 |
| 575 | Human papillomavirus load in Hybrid Capture II assay: Does increasing the cutoff improve the test?. Gynecologic Oncology, 2005, 99, 313-319. | 0.6 | 36 |
| 576 | Single-cell analysis of loss of heterozygosity at theATM gene locus in Hodgkin and Reed-Sternberg cells of Hodgkin's lymphoma:ATM loss of heterozygosity is a rare event. International Journal of Cancer, 2005, 114, 909-916. | 2.3 | 17 |

| # | Article | IF | Citations |
|---|---|---|---|
| 577 | Carcinosarcoma of the prostate: two cases with distinctive morphologic and immunohistochemical findings. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 511-516. | 1.4 | 15 |
| 578 | Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. Journal of Pathology, 2005, 205, 507-513. | 2.1 | 73 |
| 579 | CDK4 and MDM2 Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-type INK4a/ARF Locus. Cancer Research, 2005, 65, 2199-2206. | 0.4 | 93 |
| 580 | Validation of tissue microarray immunohistochemistry staining and interpretation in diffuse large B-cell lymphoma. Leukemia and Lymphoma, 2005, 46, 693-701. | 0.6 | 51 |
| 581 | Diffuse Large B-Cell Lymphoma: Clinical and Biological Characterization and Outcome According to the Nodal or Extranodal Primary Origin. Journal of Clinical Oncology, 2005, 23, 2797-2804. | 0.8 | 253 |
| 582 | Allogeneic Stem-Cell Transplantation May Overcome the Adverse Prognosis of Unmutated VH Gene in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2005, 23, 3433-3438. | 0.8 | 137 |
| 583 | Identification of Anaplastic Lymphoma Kinase Variant Translocations Using 5'RACE. , 2005, 115, 295-314. | | 1 |
| 584 | Paraffin-Embedded Cell Line Microarray (PECLIMA): Development and Validation of a High-Throughput Method for Antigen Profiling of Cell Lines. Pathobiology, 2005, 72, 225-232. | 1.9 | 22 |
| 585 | Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood, 2005, 106, 3183-3190. | 0.6 | 348 |
| 586 | Pathogenesis of Mantle-Cell Lymphoma: All Oncogenic Roads Lead to Dysregulation of Cell Cycle and DNA Damage Response Pathways. Journal of Clinical Oncology, 2005, 23, 6364-6369. | 0.8 | 186 |
| 587 | Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. Blood, 2005, 106, 3009-3009. | 0.6 | 0 |
| 588 | Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays. Haematologica, 2005, 90, 292. | 1.7 | 0 |
| 589 | Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Annals of Oncology, 2004, 15, 1484-1489. | 0.6 | 66 |
| 590 | Bullous Pemphigoid Associated With Mantle Cell Lymphoma. Archives of Dermatology, 2004, 140, 1496-9. | 1.7 | 13 |
| 591 | Protein Kinase C Î¸ Is Highly Expressed in Gastrointestinal Stromal Tumors But Not in Other Mesenchymal Neoplasias. Clinical Cancer Research, 2004, 10, 4089-4095. | 3.2 | 128 |
| 592 | Clinicopathologic Significance and Prognostic Value of Chromosomal Imbalances in Diffuse Large B-Cell Lymphomas. Journal of Clinical Oncology, 2004, 22, 3498-3506. | 0.8 | 87 |
| 593 | Anthracycline-based chemotherapy as primary treatment for intravascular lymphoma. Annals of Oncology, 2004, 15, 1215-1221. | 0.6 | 111 |
| 594 | Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the â€˜cutaneous variantâ€™1. British Journal of Haematology, 2004, 127, 173-183. | 1.2 | 535 |

| # | Article | IF | Citations |
|---|---|---|---|
| 595 | Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene, 2004, 23, 6071-6082. | 2.6 | 118 |
| 596 | Activation of mitochondrial apoptotic pathway in mantle cell lymphoma: high sensitivity to mitoxantrone in cases with functional DNA-damage response genes. Oncogene, 2004, 23, 8941-8949. | 2.6 | 23 |
| 597 | Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma. Cancer Cell, 2004, 5, 191-199. | 7.7 | 331 |
| 598 | Type IMOZ/CBP (MYST3/CREBBP)is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes and Cancer, 2004, 40, 140-145. | 1.5 | 72 |
| 599 | Enigmatic Kikuchi-Fujimoto Disease. American Journal of Clinical Pathology, 2004, 122, 141-152. | 0.4 | 331 |
| 600 | Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103, 275-282. | 0.6 | 3,574 |
| 601 | Bancos de tumores: papel en la investigaciÃ³n biomÃ©dica del presente y el futuro. CirugÃa EspaÃ±ola, 2004, 76, 4-8. | 0.1 | 1 |
| 602 | Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. New England Journal of Medicine, 2004, 351, 2159-2169. | 13.9 | 1,293 |
| 603 | Nuclear Survivin Expression in Mantle Cell Lymphoma Is Associated with Cell Proliferation and Survival. American Journal of Pathology, 2004, 164, 501-510. | 1.9 | 92 |
| 604 | BCL2 Translocation Defines a Unique Tumor Subset within the Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma. American Journal of Pathology, 2004, 165, 159-166. | 1.9 | 262 |
| 605 | Heterogeneity of genomic breakpoints in MSN-ALK translocations in anaplastic large cell lymphoma. Human Pathology, 2004, 35, 1038-1041. | 1.1 | 35 |
| 606 | Diffuse Large B-cell Lymphomas With Plasmablastic Differentiation Represent a Heterogeneous Group of Disease Entities. American Journal of Surgical Pathology, 2004, 28, 736-747. | 2.1 | 392 |
| 607 | Clonal T-cell Populations and Increased Risk for Cytotoxic T-cell Lymphomas in B-CLL Patients. American Journal of Surgical Pathology, 2004, 28, 849-858. | 2.1 | 67 |
| 608 | Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood, 2004, 103, 4251-4258. | 0.6 | 296 |
| 609 | Bronquiolitis obliterante y pÃ©nfigo paraneoplÃ¡sico: un sÃndrome paraneoplÃ¡sico autoinmune multiorgÃ¡nico. Archivos De Bronconeumologia, 2004, 40, 240-243. | 0.4 | 2 |
| 610 | The History of 34 Errors Identified in 874 Patients Analyzed at Weekly Clinical-Pathological Meetings in Two Institutions over 22 Years (1982â€“2004).. Blood, 2004, 104, 5287-5287. | 0.6 | 1 |
| 611 | Enigmatic Kikuchi-Fujimoto Disease A Comprehensive Review. American Journal of Clinical Pathology, 2004, 122, 141-152. | 0.4 | 239 |
| 612 | Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. Blood, 2004, 104, 2054-2054. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 613 | Chromosomal Imbalances in Germinal Center B-Cell-Like and Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Influence Gene Expression Signatures and Improve Gene Expression-Based Survival Prediction(the First Two Authors Contributed Equally to This Work).. Blood, 2004, 104, 415-415. | 0.6 | 1 |
| 614 | Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica, 2004, 89, 314-9. | 1.7 | 15 |
| 615 | Frequent polymorphic changes but not mutations of TRAIL receptors DR4 and DR5 in mantle cell lymphoma and other B-cell lymphoid neoplasms. Haematologica, 2004, 89, 1322-31. | 1.7 | 19 |
| 616 | Diffuse large B-cell lymphoma arising from donor lymphoid cells after renal and pancreatic transplantation. Annals of Hematology, 2003, 82, 131-135. | 0.8 | 4 |
| 617 | The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 2003, 3, 185-197. | 7.7 | 848 |
| 618 | Chimeric BCR/ABL gene detected by fluorescence in situ hybridization in three new cases of Philadelphia chromosome-negative chronic myelocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 141, 114-119. | 1.0 | 16 |
| 619 | High levels of chromosomal imbalances in typical and small-cell variants of T-cell prolymphocytic leukemia. Cancer Genetics and Cytogenetics, 2003, 147, 36-43. | 1.0 | 30 |
| 620 | Routine use of immunophenotype by flow cytometry in tissues with suspected hematological malignancies. , 2003, 56B, 8-15. | | 29 |
| 621 | Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. Journal of Experimental Medicine, 2003, 198, 851-862. | 4.2 | 1,002 |
| 622 | ZAP-70 Expression as a Surrogate for Immunoglobulin-Variable-Region Mutations in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2003, 348, 1764-1775. | 13.9 | 1,194 |
| 623 | Genetic and molecular genetic studies in the diagnosis of B-cell lymphomas I: Mantle cell lymphoma, follicular lymphoma, and Burkitt's lymphoma. Human Pathology, 2003, 34, 330-335. | 1.1 | 26 |
| 624 | Incidence and Clinical Significance of Bcl-2 / IgH Rearrangements in Follicular Lymphoma. Leukemia and Lymphoma, 2003, 44, 71-76. | 0.6 | 37 |
| 625 | Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 2003, 101, 78-84. | 0.6 | 356 |
| 626 | Follow-Up of a Large-B-Cell Pancreatic Lymphoma by Endoscopic Ultrasonography. Endoscopy, 2003, 35, 360-362. | 1.0 | 7 |
| 627 | Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood, 2003, 101, 3181-3187. | 0.6 | 81 |
| 628 | Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood, 2003, 101, 2489-2495. | 0.6 | 494 |
| 629 | Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood, 2003, 101, 4042-4046. | 0.6 | 121 |
| 630 | Easier tissue macroarray ("microchop") production. Applied Immunohistochemistry and Molecular Morphology, 2003, 11, 365. | 0.6 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 631 | Cancer Epigenetics and Methylation. Science, 2002, 297, 1807d-1808. | 6.0 | 116 |
| 632 | Alterations of Cell Cycle-Regulatory Genes in Prostate Cancer. Pathobiology, 2002, 70, 1-10. | 1.9 | 36 |
| 633 | Multiple cell cycle regulator alterations in Richter's transformation of chronic lymphocytic leukemia. Leukemia, 2002, 16, 1028-1034. | 3.3 | 34 |
| 634 | Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Annals of Oncology, 2002, 13, 523-530. | 0.6 | 42 |
| 635 | ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood, 2002, 99, 238-244. | 0.6 | 151 |
| 636 | Analysis of the IgVH somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood, 2002, 99, 1299-1304. | 0.6 | 158 |
| 637 | CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood, 2002, 100, 4602-4608. | 0.6 | 67 |
| 638 | Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood, 2002, 100, 1810-1816. | 0.6 | 108 |
| 639 | Diversity of Genomic Breakpoints in TFG-ALK Translocations in Anaplastic Large Cell Lymphomas. American Journal of Pathology, 2002, 160, 1487-1494. | 1.9 | 102 |
| 640 | Genetic Imbalances in Progressed B-Cell Chronic Lymphocytic Leukemia and Transformed Large-Cell Lymphoma (Richter's Syndrome). American Journal of Pathology, 2002, 161, 957-968. | 1.9 | 86 |
| 641 | The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma. New England Journal of Medicine, 2002, 346, 1937-1947. | 13.9 | 3,474 |
| 642 | Tyrosine phosphorylation in human lymphomas. The Histochemical Journal, 2002, 34, 545-552. | 0.6 | 4 |
| 643 | Pharmacokinetics and tissue distribution of intravenous pefloxacin for antibiotic prophylaxis in biliary surgery. Biopharmaceutics and Drug Disposition, 2002, 23, 293-300. | 1.1 | 1 |
| 644 | Primary follicular lymphoma arising in the ampulla of Vater. Annals of Hematology, 2002, 81, 228-231. | 0.8 | 28 |
| 645 | True anti-anionic phospholipid immunoglobulin M antibodies can exert lupus anticoagulant activity. British Journal of Haematology, 2002, 116, 875-886. | 1.2 | 14 |
| 646 | Tumours of histiocytes and accessory dendritic cells: an immunohistochemical approach to classification from the International Lymphoma Study Group based on 61 cases. Histopathology, 2002, 41, 1-29. | 1.6 | 576 |
| 647 | Clonally unrelated Hodgkin's disease following autologous stem cell transplant for B-cell lymphoma. British Journal of Haematology, 2002, 116, 329-333. | 1.2 | 5 |
| 648 | Limitations of Gallium-67 SPECT in histological transformation of chronic lymphocytic leukaemia: an analysis of 13 patients with clinically suspected Richter's syndrome. British Journal of Haematology, 2002, 119, 484-487. | 1.2 | 10 |

| # | Article | IF | Citations |
|---|---|---|---|
| 649 | Molecular histogenesis of plasmablastic lymphoma of the oral cavity. British Journal of Haematology, 2002, 119, 622-628. | 1.2 | 77 |
| 650 | Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?. Leukemia, 2002, 16, 1454-1459. | 3.3 | 38 |
| 651 | Blastic Natural Killer Cell Leukemia/Lymphoma Presenting as Overt Leukemia. Clinical Lymphoma and Myeloma, 2001, 2, 178-182. | 2.1 | 6 |
| 652 | Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. Blood, 2001, 97, 3513-3520. | 0.6 | 58 |
| 653 | Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood, 2001, 98, 2771-2777. | 0.6 | 184 |
| 654 | Cutaneous lymphocyte-associated antigen (CLA) expression in a lymphoblastoid mantle cell lymphoma presenting with skin lesions. Comparison with other clinicopathologic presentations of mantle cell lymphoma. Journal of Cutaneous Pathology, 2001, 28, 256-264. | 0.7 | 32 |
| 655 | Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer, 2001, 91, 1557-1562. | 2.0 | 22 |
| 656 | Expression of cathepsins B and S in the progression of prostate carcinoma. International Journal of Cancer, 2001, 95, 51-55. | 2.3 | 134 |
| 657 | Small-vessel vasculitis surrounding a spared temporal artery: Clinical and pathologic findings in a series of twenty-eight patients. Arthritis and Rheumatism, 2001, 44, 1387-1395. | 6.7 | 105 |
| 658 | Tissue macroarrays ("microchops") for gene expression analysis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 591-594. | 1.4 | 17 |
| 659 | Molecular Characterization of a New ALK Translocation Involving Moesin (MSN-ALK) in Anaplastic Large Cell Lymphoma. Laboratory Investigation, 2001, 81, 419-426. | 1.7 | 158 |
| 660 | Differential Expression of cdc25 Cell-Cycleâ€“Activating Phosphatases in Human Colorectal Carcinoma. Laboratory Investigation, 2001, 81, 465-473. | 1.7 | 74 |
| 661 | Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia, 2001, 15, 445-451. | 3.3 | 105 |
| 662 | Microsatellite instability analysis in typical and progressed mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Haematologica, 2001, 86, 181-6. | 1.7 | 14 |
| 663 | BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Research, 2001, 61, 2409-12. | 0.4 | 221 |
| 664 | Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer, 2001, 91, 1557-62. | 2.0 | 5 |
| 665 | The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. Cancer Research, 2001, 61, 8820-9. | 0.4 | 185 |
| 666 | Nodal Marginal Zone Lymphoma. American Journal of Surgical Pathology, 2000, 24, 315. | 2.1 | 9 |

| # | Article | IF | Citations |
|---|---|---|---|
| 667 | Pharmacokinetics of Ofloxacin Enantiomers after Intravenous Administration for Antibiotic Prophylaxis in Biliary Surgery. Journal of Clinical Pharmacology, 2000, 40, 869-874. | 1.0 | 10 |
| 668 | Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148. | | 17 |
| 669 | cdc25a and the splicing variant cdc25b2, but not cdc25B1, -B3 or -C, are over-expressed in aggressive human non-Hodgkin's lymphomas. , 2000, 89, 148-152. | | 56 |
| 670 | Loss of the TSG101 leucine zipper domain in aggressive non-Hodgkin's lymphomas. Leukemia, 2000, 14, 2014-2016. | 3.3 | 1 |
| 671 | Assessment of Genotype and Molecular Evolution of Hepatitis C Virus in Formalin-Fixed Paraffin-Embedded Liver Tissue from Patients With Chronic Hepatitis C Virus Infection. Laboratory Investigation, 2000, 80, 851-856. | 1.7 | 9 |
| 672 | Rapid Diagnosis of Acute Promyelocytic Leukemia by Analyzing the Immunocytochemical Pattern of the PML Protein With the Monoclonal Antibody PG-M3. American Journal of Clinical Pathology, 2000, 114, 786-792. | 0.4 | 25 |
| 673 | INK4a/ARFLocus Alterations in Human Non-Hodgkin's Lymphomas Mainly Occur in Tumors with Wild-Type p53 Gene. American Journal of Pathology, 2000, 156, 1987-1996. | 1.9 | 83 |
| 674 | A new variant anaplastic lymphoma kinase (ALK)-fusion protein (ATIC-ALK) in a case of ALK-positive anaplastic large cell lymphoma. Cancer Research, 2000, 60, 793-8. | 0.4 | 115 |
| 675 | Expression of Beta-Integrin Adhesion Molecules in Non-Hodgkin's Lymphoma: Correlation With Clinical and Evolutive Features. Journal of Clinical Oncology, 1999, 17, 1869-1869. | 0.8 | 35 |
| 676 | TRK-Fused Gene (TFG) Is a New Partner of ALK in Anaplastic Large Cell Lymphoma Producing Two Structurally DifferentTFG-ALK Translocations. Blood, 1999, 94, 3265-3268. | 0.6 | 266 |
| 677 | Possible carcinogenic effects of X-rays in a transgenerational study with CBA mice. Carcinogenesis, 1999, 20, 325-332. | 1.3 | 31 |
| 678 | Ito Cell Tumor: Immunohistochemical Investigations of a Rare Lesion in the Liver of Mice. Toxicologic Pathology, 1999, 27, 364-369. | 0.9 | 7 |
| 679 | c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkinâ€™s lymphomas. Leukemia, 1999, 13, 2087-2093. | 3.3 | 44 |
| 680 | Anaplastic large-cell lymphoma with rapid evolution to leukemic phase. Annals of Hematology, 1999, 78, 478-482. | 0.8 | 36 |
| 681 | Translocation (11;14)(q13;q32) and Preferential Involvement of Chromosomes 1, 2, 9, 13, and 17 in Mantle Cell Lymphoma. Cancer Genetics and Cytogenetics, 1999, 111, 92-98. | 1.0 | 31 |
| 682 | Quality control of three methods for lung tumorigenesis studies. Experimental and Toxicologic Pathology, 1999, 51, 99-104. | 2.1 | 6 |
| 683 | Disregulation of p16MTS1/CDK4I protein and mRNA expression is associated with gene alterations in squamous-cell carcinoma of the larynx. , 1999, 81, 705-711. | | 19 |
| 684 | Expression of p27/kip1 is down-regulated in human prostate carcinoma progression. , 1999, 187, 563-566. | | 41 |

| # | Article | IF | Citations |
|---|---|---|---|
| 685 | Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. , 1999, 189, 288-293. | | 44 |
| 686 | Biochemical Detection of Novel Anaplastic Lymphoma Kinase Proteins in Tissue Sections of Anaplastic Large Cell Lymphoma. American Journal of Pathology, 1999, 154, 1657-1663. | 1.9 | 53 |
| 687 | Primary Nodal Marginal Zone Lymphomas of Splenic and MALT Type. American Journal of Surgical Pathology, 1999, 23, 59-68. | 2.1 | 147 |
| 688 | Î²-HCG Aberrant Expression in Primary Mediastinal Large B-Cell Lymphoma. American Journal of Surgical Pathology, 1999, 23, 717-721. | 2.1 | 16 |
| 689 | Mantle-cell lymphoma. Seminars in Hematology, 1999, 36, 115-27. | 1.8 | 262 |
| 690 | Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood, 1999, 93, 4365-74. | 0.6 | 218 |
| 691 | Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood, 1999, 94, 3509-15. | 0.6 | 162 |
| 692 | TRK-fused gene (TFG) is a new partner of ALK in anaplastic large cell lymphoma producing two structurally different TFG-ALK translocations. Blood, 1999, 94, 3265-8. | 0.6 | 127 |
| 693 | Mantle cell lymphoma. , 1998, 82, 567-575. | | 302 |
| 694 | p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. Journal of Pathology, 1998, 184, 265-271. | 2.1 | 46 |
| 695 | Collagenase-3 expression is associated with advanced local invasion in human squamous cell carcinomas of the larynx. , 1998, 186, 144-150. | | 79 |
| 696 | Ki-ras gene mutations and absence ofp53 gene mutations in spontaneous and urethane-induced early lung lesions in CBA/J mice. Molecular Carcinogenesis, 1998, 21, 251-260. | 1.3 | 33 |
| 697 | A marginal zone pattern may be found in different varieties of nonâ€Hodgkin's lymphoma: the morphology and immunohistology of splenic involvement by Bâ€cell lymphomas simulating splenic marginal zone lymphoma. Histopathology, 1998, 33, 230-239. | 1.6 | 67 |
| 698 | Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. British Journal of Haematology, 1998, 102, 1301-1306. | 1.2 | 36 |
| 699 | Mantle Cell Lymphomas Lack Expression of p27kip1, a Cyclin-Dependent Kinase Inhibitor. American Journal of Pathology, 1998, 153, 175-182. | 1.9 | 109 |
| 700 | Pharmacokinetics and Tissue Distribution of Intravenous Ofloxacin for Antibiotic Prophylaxis in Biliary Surgery. Clinical Drug Investigation, 1998, 15, 491-496. | 1.1 | 6 |
| 701 | Cell cycle regulators and their abnormalities in breast cancer. Journal of Clinical Pathology, 1998, 51, 305-309. | 2.1 | 32 |
| 702 | Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance.. Journal of Clinical Oncology, 1998, 16, 35-40. | 0.8 | 47 |

| # | Article | IF | Citations |
|---|---|---|---|
| 703 | p16INK4a Gene Inactivation by Deletions, Mutations, and Hypermethylation Is Associated With Transformed and Aggressive Variants of Non-Hodgkin's Lymphomas. Blood, 1998, 91, 2977-2984. | 0.6 | 266 |
| 704 | Risk of relapse and clinicoâ€pathological features in 103 patients with diffuse largeâ€cell lymphoma in complete response after firstâ€line treatment. European Journal of Haematology, 1998, 61, 59-64. | 1.1 | 11 |
| 705 | p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood, 1998, 91, 2977-84. | 0.6 | 64 |
| 706 | Cathepsin L2, a novel human cysteine proteinase produced by breast and colorectal carcinomas. Cancer Research, 1998, 58, 1624-30. | 0.4 | 117 |
| 707 | cdc25 cell cycle-activating phosphatases and c-myc expression in human non-Hodgkin's lymphomas. Cancer Research, 1998, 58, 1762-7. | 0.4 | 54 |
| 708 | Hyperplastic Lesions of the Larynx. Experience of the Barcelona Group. Acta Oto-Laryngologica, 1997, 117, 43-46. | 0.3 | 4 |
| 709 | Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. British Journal of Cancer, 1997, 75, 969-977. | 2.9 | 54 |
| 710 | Differential expression of galectin 3 and galectin 1 in colorectal cancer progression. Gastroenterology, 1997, 113, 1906-1915. | 0.6 | 198 |
| 711 | p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx. Oncogene, 1997, 15, 1445-1453. | 2.6 | 45 |
| 712 | Subcutaneous soft tissue tumours at the site of implanted microchips in mice. Experimental and Toxicologic Pathology, 1997, 49, 197-200. | 2.1 | 49 |
| 713 | Massive crystal-storing histiocytosis associated with low-grade malignant B-cell lymphoma of MALT-Type of the parotid gland. Diagnostic Cytopathology, 1997, 17, 148-152. | 0.5 | 47 |
| 714 | p21WAF1/CIP1 AND MDM2 EXPRESSION IN NON-HODGKIN'S LYMPHOMA AND THEIR RELATIONSHIP TO p53 STATUS: A p53+, MDM2â˜, p21â˜ IMMUNOPHENOTYPE ASSOCIATED WITH MISSENSE p53 MUTATIONS. , 1997, 181, 51-61. | | 55 |
| 715 | GALECTIN-3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON-NEOPLASTIC THYROID TISSUE. , 1997, 181, 80-86. | | 128 |
| 716 | CYCLIN D1 AND RETINOBLASTOMA GENE EXPRESSION IN HUMAN BREAST CARCINOMA: CORRELATION WITH TUMOUR PROLIFERATION AND OESTROGEN RECEPTOR STATUS. , 1997, 182, 160-166. | | 63 |
| 717 | p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. , 1997, 183, 156-163. | | 44 |
| 718 | p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. , 1997, 183, 156. | | 1 |
| 719 | The monoclonal antibody ALK1 identifies a distinct morphological subtype of anaplastic large cell lymphoma associated with 2p23/ALK rearrangements. American Journal of Pathology, 1997, 151, 343-51. | 1.9 | 107 |
| 720 | Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood, 1997, 89, 272-80. | 0.6 | 60 |

| # | Article | IF | Citations |
|---|---|---|---|
| 721 | p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood, 1996, 87, 3351-3359. | 0.6 | 255 |
| 722 | CNS involvement in mantle-cell lymphoma.. Journal of Clinical Oncology, 1996, 14, 941-944. | 0.8 | 69 |
| 723 | Detection of thebcl-1 Rearrangement at the Major Translocation Cluster in Frozen and Paraffin-Embedded Tissues of Mantle Cell Lymphomas by Polymerase Chain Reaction. American Journal of Clinical Pathology, 1996, 105, 532-537. | 0.4 | 44 |
| 724 | Six-year Follow-up of Primary Small Cell Carcinoma of the Esophagus Showing a Complete Response: A Case Report. Japanese Journal of Clinical Oncology, 1996, 26, 180-184. | 0.6 | 16 |
| 725 | Expression of intercellular adhesion moleculeâ€3 (ICAMâ€3/CD50) in malignant lymphoproliferative disorders and solid tumors. Tissue Antigens, 1996, 48, 271-277. | 1.0 | 9 |
| 726 | OVEREXPRESSION OF THE 67-kD LAMININ RECEPTOR CORRELATES WITH TUMOUR PROGRESSION IN HUMAN COLORECTAL CARCINOMA. , 1996, 179, 376-380. | | 104 |
| 727 | UTILITY OF BONE MARROW AND LIVER BIOPSIES FOR STAGING CUTANEOUS T-CELL LYMPHOMA. International Journal of Dermatology, 1996, 35, 450-454. | 0.5 | 11 |
| 728 | Immunohistochemical expression of proliferating cell nuclear antigen (PCNA) in archival samples of nonâ€Hodgkin's lymphoma. Correlation with flow cytometry proliferation results. European Journal of Haematology, 1996, 56, 252-253. | 1.1 | 0 |
| 729 | Papillary Transitional Cell Carcinoma. American Journal of Surgical Pathology, 1996, 20, 125. | 2.1 | 5 |
| 730 | Pathological, Immunological, and Molecular Features of Hodgkin's Disease Associated with HIV Infection. American Journal of Surgical Pathology, 1996, 20, 1520-1524. | 2.1 | 61 |
| 731 | Expression of retinoblastoma gene product (pRb) in mantle cell lymphomas. Correlation with cyclin D1 (PRAD1/CCND1) mRNA levels and proliferative activity. American Journal of Pathology, 1996, 148, 1591-600. | 1.9 | 44 |
| 732 | Mantle cell lymphoma. Accurate diagnosis yields new clinical insights. Archives of Pathology and Laboratory Medicine, 1996, 120, 12-4. | 1.2 | 15 |
| 733 | p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood, 1996, 87, 3351-9. | 0.6 | 55 |
| 734 | Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. Cancer Research, 1996, 56, 1746-50. | 0.4 | 47 |
| 735 | A Clinicopathological Study of 13 Cases. American Journal of Surgical Pathology, 1995, 19, 1146-1157. | 2.1 | 128 |
| 736 | Schistosomiasis: an unusual cause of tubal infertility. Human Reproduction, 1995, 10, 1725-1727. | 0.4 | 26 |
| 737 | Deletions in the Epstein-Barr virus latent membrane protein-1 oncogene in Hodgkin's disease. Journal of Clinical Pathology, 1995, 48, M184-M187. | 2.1 | 24 |
| 738 | Increased expression of the PRADâ€1/CCND1 gene in hairy cell leukaemia. British Journal of Haematology, 1995, 91, 1025-1030. | 1.2 | 97 |

| # | Article | IF | Citations |
|---|---|---|---|
| 739 | Short-term outcome analysis of a randomized study comparing laparoscopic vs open colectomy for colon cancer. Surgical Endoscopy and Other Interventional Techniques, 1995, 9, 1101-5. | 1.3 | 310 |
| 740 | p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors. Journal of Pathology, 1995, 175, 181-188. | 2.1 | 58 |
| 741 | Mucosal mantle cell (centrocytic) lymphomas. Histopathology, 1995, 26, 413-422. | 1.6 | 38 |
| 742 | Presenting features, natural history, and prognostic factors in localized nonâ€Hodgkin's lymphomas: analysis of 117 cases from a single institution. European Journal of Haematology, 1995, 55, 217-222. | 1.1 | 3 |
| 743 | European Lymphoma Task Force (ELTF): Report of the workshop on Mantle Cell Lymphoma (MCL). Annals of Oncology, 1994, 5, 507-511. | 0.6 | 130 |
| 744 | PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood, 1994, 84, 2726-2732. | 0.6 | 325 |
| 745 | Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma.. Journal of Clinical Oncology, 1994, 12, 1343-1348. | 0.8 | 185 |
| 746 | Taqlpolymorphism of the human tissue inhibitor of metallo-proteinases-2 (Timp2) gene. Human Molecular Genetics, 1994, 3, 218-218. | 1.4 | 0 |
| 747 | Low-Grade Lymphoma: Clinical and Prognostic Studies in a Series of 143 Patients from a Single Institution. Leukemia and Lymphoma, 1994, 15, 159-165. | 0.6 | 16 |
| 748 | Prognostic significance of the loss of heterozygosity of nm23-h1 and p53 genes in human colorectal carcinomas. Cancer, 1994, 73, 2913-2921. | 2.0 | 65 |
| 749 | Immunohistochemical characterization of inflammatory cells and immunologic activation markers in muscle and nerve biopsy specimens from patients with systemic polyarteritis nodosa. Arthritis and Rheumatism, 1994, 37, 1055-1061. | 6.7 | 67 |
| 750 | Elephantiasis in SÃ£o TomÃ© and PrÃncipe. Acta Tropica, 1994, 57, 29-34. | 0.9 | 22 |
| 751 | Spectrum of glandular differentiation in experimental carcinoma of the esophagus induced by 2,6-dimethylnitrosomorpholine under the influence of esophagojejunostomy. Experimental and Toxicologic Pathology, 1994, 46, 41-49. | 2.1 | 16 |
| 752 | nm23-H1 Expression and disease recurrence after surgical resection of small hepatocellular carcinoma. Gastroenterology, 1994, 107, 486-491. | 0.6 | 27 |
| 753 | Role of Zinc in the Process of Pancreatic Fibrosis in Chronic Alcoholic Pancreatitis. Pancreas, 1994, 9, 270-274. | 0.5 | 8 |
| 754 | PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood, 1994, 84, 2726-2732. | 0.6 | 8 |
| 755 | Cathepsin B expression in colorectal carcinomas correlates with tumor progression and shortened patient survival. American Journal of Pathology, 1994, 145, 301-9. | 1.9 | 158 |
| 756 | Increased gelatinase A (MMP-2) and cathepsin B activity in invasive tumor regions of human colon cancer samples. American Journal of Pathology, 1994, 145, 1285-90. | 1.9 | 174 |

| # | Article | IF | Citations |
|---|---|---|---|
| 757 | PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood, 1994, 84, 2726-32. | 0.6 | 77 |
| 758 | PRAD-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Research, 1994, 54, 4813-7. | 0.4 | 189 |
| 759 | Expression of Cytokeratins in Squamous Cell Carcinomas of the Larynx: Immunohistochemical Analysis and Correlation with Prognostic Factors*. Pathology Research and Practice, 1993, 189, 275-282. | 1.0 | 18 |
| 760 | Vulvar lesion in a Spanish traveler to Mali. International Journal of Gynecology and Obstetrics, 1993, 41, 94-95. | 1.0 | 2 |
| 761 | Glomerulocystic Kidney Disease: A Single Entity?. Nephron, 1993, 63, 100-103. | 0.9 | 9 |
| 762 | T-Cell Lymphoblastic Lymphoma with Blood Eosinophilia and Associated Myeloid Malignancy. American Journal of Surgical Pathology, 1993, 17, 92-93. | 2.1 | 2 |
| 763 | Comparative Study of Spleen Pathology in Drug Abusers With Thrombocytopenia Related to Human Immunodeficiency Virus Infection and in Patients With Idiopathic Thrombocytopenic Purpura:A Morphometric, Immunohistochemical, and Ultrastructural Study. American Journal of Clinical Pathology, 1993, 100, 633-642. | 0.4 | 9 |
| 764 | Inverse Modulation of Steady-State Messenger RNA Levels of Two Non-Integrin Laminin-Binding Proteins in Human Colon Carcinoma. Journal of the National Cancer Institute, 1992, 84, 1161-1169. | 3.0 | 90 |
| 765 | Evaluation of Basement Membrane Components and the 72 kDa Type IV Collagenase in Serous Tumors of the Ovary. American Journal of Surgical Pathology, 1992, 16, 500-507. | 2.1 | 104 |
| 766 | Prognostic Value of CA 19.9 Levels in Colorectal Cancer. Annals of Surgery, 1992, 216, 55-59. | 2.1 | 101 |
| 767 | Distribution of the 72-kd type IV collagenase in nonneoplastic and neoplastic thyroid tissue. Human Pathology, 1992, 23, 1395-1401. | 1.1 | 107 |
| 768 | Small cell carcinoma of the endometrium with associated ocular paraneoplastic syndrome. Cancer, 1992, 69, 2283-2288. | 2.0 | 66 |
| 769 | Detection of laminin receptor mRNA in human cancer cell lines and colorectal tissues by in situ hybridization. American Journal of Pathology, 1992, 141, 1073-83. | 1.9 | 18 |
| 770 | Patterns of basement membrane laminin distribution in nonneoplastic and neoplastic thyroid tissue. Modern Pathology, 1992, 5, 540-6. | 2.9 | 8 |
| 771 | Human Chorionic Gonadotropin in Esophageal Carcinomas. Pathology Research and Practice, 1991, 187, 44-49. | 1.0 | 1 |
| 772 | Human Chorionic Gonadotropin in Esophageal Carcinomas An Immunohistochemical Study. Pathology Research and Practice, 1991, 187, 503-507. | 1.0 | 4 |
| 773 | Ki-1+ anaplastic large-cell lymphoma of T-cell origin in an HIV-infected patient. Aids, 1991, 5, 751-756. | 1.0 | 32 |
| 774 | Non-Hodgkin's Lymphomas of Nasal Cavity and Paranasal Sinuses An Immunohistochemical Study. American Journal of Clinical Pathology, 1991, 96, 184-190. | 0.4 | 74 |

| # | Article | IF | Citations |
|---|---|---|---|
| 775 | Quantitative measurement of fibrosis in pancreatic tissue. International Journal of Gastrointestinal Cancer, 1991, 10, 23-29. | 0.4 | 19 |
| 776 | BglII and EcoRI polymorphism of the human nm23-H1 gene (NME1). Nucleic Acids Research, 1991, 19, 6663-6663. | 6.5 | 17 |
| 777 | Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. Cancer Research, 1991, 51, 4436-42. | 0.4 | 126 |
| 778 | Hodgkin's disease in patients with antibodies to human immunodeficiency virus a study of 22 patients. Cancer, 1990, 65, 2248-2254. | 2.0 | 86 |
| 779 | Cardiac hemangioma with papillary endothelial hyperplasia: Report of a resected case and review of the literature. Annals of Thoracic Surgery, 1990, 49, 305-308. | 0.7 | 56 |
| 780 | Expression of lymphocyte, macrophage and class I and II major histocompatibility complex antigens in normal human dorsal root ganglia. Journal of the Neurological Sciences, 1990, 98, 203-211. | 0.3 | 24 |
| 781 | Are there diagnostic histologic features of porphyria cutanea tarda in liver biopsy specimens?. Liver, 1990, 10, 185-190. | 0.1 | 28 |
| 782 | Immunohistochemical analysis of the immune reaction in the nervous system in paraneoplastic encephalomyelitis. Neurology, 1990, 40, 219-219. | 1.5 | 108 |
| 783 | Multiple Organ Involvement by Legionella pneumophila in a Fatal Case of Legionnaires' Disease. Journal of Infectious Diseases, 1989, 159, 809-809. | 1.9 | 31 |
| 784 | Placental proteins in high-grade urothelial neoplasms. An immunohistochemical study of human chorionic gonadotropin, human placental lactogen, and pregnancy-specific beta-1-glycoprotein. Cancer, 1989, 63, 2497-2504. | 2.0 | 50 |
| 785 | Regional distribution of glycoconjugates in normal, transitional and neoplastic human colonic mucosa. Virchows Archiv A, Pathological Anatomy and Histopathology, 1989, 415, 347-356. | 1.4 | 35 |
| 786 | Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunologic activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis and Rheumatism, 1989, 32, 884-93. | 6.7 | 80 |
| 787 | Distribution and changes of glycoconjugates in rat colonic mucosa during development. Histochemistry, 1988, 90, 261-270. | 1.9 | 27 |
| 788 | Large B-cell lymphoma presenting with lytic bone lesions and hypercalcaemia. Histopathology, 1988, 13, 477-478. | 1.6 | 1 |
| 789 | Lectin binding patterns in normal and neoplastic colonic mucosa. Diseases of the Colon and Rectum, 1988, 31, 892-899. | 0.7 | 33 |
| 790 | Recurrent Arterial Thrombosis in a Patient with Giant-cell Arteritis and Raised Anticardiolipin Antibody Levels. Rheumatology, 1988, 27, 164-165. | 0.9 | 21 |
| 791 | Renal Hemangioma and Renal Artery Aneurysm in the Klippel-Trenaunay Syndrome. Journal of Urology, 1988, 140, 134-136. | 0.2 | 32 |
| 792 | Intestinal Lymphoma in a Patient with Chronic Lymphocytic Leukemia of Atypical Phenotype: Richterâ€™s Syndrome of Unusual Presentation. Acta Haematologica, 1988, 80, 116-119. | 0.7 | 6 |

| # | Article | IF | Citations |
|---|---|---|---|
| 793 | Epithelioid hemangioendothelioma of the liver: report of two cases. Liver, 1988, 8, 105-110. | 0.1 | 14 |
| 794 | Podoconiosis in Aequatorial Guinea. Report of two cases from different geological environments. Tropical and Geographical Medicine, 1988, 40, 359-64. | 0.1 | 23 |
| 795 | CLINICAL PRESENTATION OF SCHISTOSOMA INTERCALATATUM INFESTATION. Lancet, The, 1987, 329, 1139-1140. | 6.3 | 18 |
| 796 | Ferritin Immunohistochemical Localization in Normal and Neoplastic Colonic Mucosa. International Journal of Biological Markers, 1987, 2, 177-183. | 0.7 | 5 |
| 797 | Human chorionic gonadotropin in colorectal carcinoma an immunohistochemical study. Cancer, 1987, 59, 1611-1616. | 2.0 | 36 |
| 798 | Ferritin immunohistochemical localization in normal and neoplastic colonic mucosa. International Journal of Biological Markers, 1987, 2, 177-83. | 0.7 | 4 |
| 799 | Tuberculosis-associated hemophagocytic syndrome:A systemic process. Cancer, 1986, 58, 2640-2645. | 2.0 | 65 |
| 800 | AL-type amyloidosis and light chain deposition disease. Clinical Nephrology, 1986, 25, 220. | 0.4 | 0 |
| 801 | Dermal cylindromas (Turban tumour) and eccrine spiradenomas in a patient with membranous basal cell adenoma of the parotid gland. Journal of Cutaneous Pathology, 1985, 12, 72-79. | 0.7 | 47 |
| 802 | Central nervous system heterotopia in the lung of a fetus with cranial malformation. Virchows Archiv A, Pathological Anatomy and Histology, 1981, 391, 117-122. | 1.3 | 11 |
| 803 | Mantle cell lymphoma pathology update in the 2016 WHO classification. Annals of Lymphoma, 0, 3, 3-3. | 4.5 | 12 |
| 804 | Aggressive B-cell lymphomasâ€"from morphology to molecular pathogenesis. Annals of Lymphoma, 0, 3, 1-1. | 4.5 | 19 |